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Abstract 
The roles of the folate receptor and an anion carrier in the uptake of 5-
methyltetrahydrofolate (5-MeH4folate) were studied in cultured human (KB) 
cells using radioactive 5-MeB4folate. Binding of the 5-MeH4folate was inhibited 
by folic acid, but not by probenecid, an anion carrier inhibitor. The 
internalization of 5-MeH4folate was inhibited by low temperature, folic acid, 
probenecid and methotrexate. Prolonged incubation of cells in the presence of 
high concentrations of probenecid appeared to inhibit endocytosis of folate-
receptors as well as the anion carrier. The Vmax and KM values for the carrier 
were 8.65 ± 0.55 pmol/min/mg cell protein and 3.74 ± 0.54j.l.M, respectively. The 
transport of 5-MeH4folate was competitively inhibited by folic acid, probenecid 
and methotrexate. The carrier dissociation constants for folic acid, probenecid 
and methotreate were 641 j.l.M, 2.23 mM and 13.8 j.l.M, respectively. Kinetic 
analysis suggests that 5-MeB4folate at physiological concentration is transported 
through an anion carrier with the characteristics of the reduced-folate carrier 
after 5-MeH4folate is endocytosed by folate receptors in KB cells. Our data with 
KB cells suggest that folate receptors and probenecid-sensitive carriers work in 
tandem to transport 5-MeH4folate to the cytoplasm of cells, based upon the 
assumption that 1 mM probenecid does not interfere with the acidification of the 
vesicle where the folate receptors are endocytosed. 
Oligodeoxynucleotides designed to hybridize to specific mRNA sequences 
(antisense oligonucleotides) or double stranded DNA sequences have been used 
to inhibit the synthesis of a number of cellular and viral proteins (Crooke, S. T. 
(1993) FASEB J. 7, 533-539; Carter, G. and Lemoine, N. R. (1993) Br. J. Cacer 67, 
869-876; Stein, C. A. and cohen, J. S. (1988) Cancer Res. 48, 2659-2668). 
However, the distribution of the delivered oligonucleotides in the cell, i.e., in the 
vi 
cytoplasm or in the nucleus has not been clearly defined. We studied the kinetics 
of oligonucleotide transport into the cell nucleus using reconstituted cell nuclei 
as a model system. We present evidences here that oligonucleotides can freely 
diffuse into reconstituted nuclei. Our results are consistent with the reports by 
Leonetti et al. (Proc . Natl. Acad. Sci. USA, Vol. 88, pp. 2702-2706, April 1991), 
which were published while we were carrying this research independently. We 
also investigated whether a synthetic nuclear localization signal (NLS) peptide of 
SV40 T antigen could be used for the nuclear targeting of oligonucleotides. We 
synthesized a nuclear localization signal peptide-conjugated oligonucleotide to 
see if a nuclear localization signal peptide can enhance the uptake of 
oligonucleotides into reconstituted nuclei of Xenopus. Uptake of the NLS 
peptide-conjugated oligonucleotide was comparable to the control 
oligonucleotide at similar concentrations, suggesting that the NLS signal peptide 
does not significantly enhance the nuclear accumulation of oligonucleotides. 
This result is probably due to the small size of the oligonucleotide. 
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Chapter 1: Introduction 
2 
OBJECTIVES 
Most drugs administered by oral or parenteral routes such as intravascular 
administration, intramuscular administration, subcutaneous administration, 
adsorption through the skin, or by inhalation reach the organs and tissues of the 
body through the blood circulation (1). Selectively acting drugs release their 
biological effects by reaction with specific receptor sites associated with nucleic 
acids, enzymes, or other proteins or biomacromolecules (2). Since many of the 
drug receptors are located ins~de cells, the administered drugs must cross cellular 
and intracellular membranes to reach the sites of action after reaching the target 
tissue (2) . If drugs are designed to act in the cell nucleus, methods need to be 
developed to deliver the drugs into the cell cytoplasm and into the nucleus 
sequentially (Fig. 1). 
Cellular membranes are two-dimensional bilayers of oriented lipids 
containing globular proteins according to the fluid mosaic model proposed by 
Singer and Nicolson (Fig. 2, ref. 3). Cellular membranes are highly selective 
permeability barriers. Transport of substances across cellular membranes can 
occur via several different mechanisms (Figs. 3 and 4, refs. 4 a, 4b). Small 
lipophilic substances or gas molecules can freely diffuse into the cell across the 
cellular membrane (4a) . Transport of small ions and molecules such as sodium 
ion, potassium ion, calcium ion and amino acids occurs through membrane 
carriers (4a). In most animal cells, clathrin-coated pits and membrane vesicles 
provide a specialized pathway for taking up specific macromolecules from the 
extracellular fluid, a process called receptor-mediated endocytosis (Fig. 4, ref. 
4b). Extracellular fluid containing many solutes can be trapped in the vesicles 
and is ingested as well (pinocytosis, ref. 6). In most cells, the great majority of 
endocytic vesicles ultimately fuse with small vesicles called primary lysosomes 
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to form secondary lysosomes, which are specialized sites of intracellular 
digestion (see Fig. 4, ref. 4b). Liposomes, artificial membrane vesicles, have been 
introduced as drug carriers since liposome encapsulation of drugs reduces 
nonspecific interactions of the drugs with undesired tissues and thereby reduces 
the toxicity of the drugs (review 5). Drug-loaded liposomes can be taken up by 
cells via the clathrin-coated pit endocytic pathway (Fig. 5, ref. 6) . If drug-loaded 
liposomes are taken up by the clathrin-coated pit endocytic pathway, the 
liposomes are eventually delivered to lysosomes in the cell, where the liposomal 
membranes are disassembled by enzymes and the liposome contents are released 
in the lumen of the lysosomes. Since lysosomes contain various digestive 
" 
enzymes, therapeutic reagents could be susceptible to the enzymes and could 
lose their therapeutic activity before they reach the desired intracellular locations 
such as the cytoplasm or the cell nucleus (Fig. 5). 
Cells need vitamins for survival. Folic acid, a vitamin, and its derivatives 
such as 5-methyltetrahydrofolate (see Fig. 1 in Chapter 2.) are involved in the 
synthesis of purines and pyrimidines and therefore the genetic material of the 
cell. Therefore, cells have a special need for folic acid or its derivatives for 
proliferation (7). Studies have shown that folates are taken up by cells by folate 
receptor-mediated endocytosis (8) . Recent reports have also suggested that the 
folate receptor-mediated endocytosis pathway might be useful as a new delivery 
route for large molecule such as bacterial or plant toxins, oligonucleotides, or 
liposome-encapsulated drugs (Fig. 6, refs. 9, 10). Leamon et al. (9) reported that 
proteins covalently conjugated to folic acid were taken up by folate receptor-
mediated endocytosis and were stable for a prolonged period of time inside the 
cell. Leamon et al. (10) recently reported that folate-conjugated plant toxin 
(momordin) could be delivered to the cell cytoplasm from outside of the cell. 
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Although the intracellular location of proteins other than toxins were not clearly 
defined in their works, these results suggest that the folate receptor endocytic 
pathway might be distinct from the clathrin-coated vesicle endocytic pathway. If 
the folate receptor pathway is distinct from the clathrin-coated vesicle pathway, 
and the endocytosed vesicles containing folate receptors do not fuse with 
lysosomes, this would be very promising for the delivery of drugs susceptible to 
lysosomal enzymes. In addition, some cancer cells have a great need for folates 
for cell division and express a large number of folate receptors on the cell surface, 
which could be available for drug delivery and targeting. 
Recent studies have shown that there are several distinct mechanisms for 
folate uptake (review 11) . These studies have shown that cells have 
transmembrane carriers as well as folate receptors for folate uptake (11) . 
Chemotherapeutic agents such as methotrexate and other antifolate reagents are 
known to be taken up by either one of the two folate uptake pathways (11) . 
However, the interrelationship of the two systems in the uptake of folate or 
antifolate compounds has not been clearly defined (8, 11). It has not been clearly 
established whether the folate receptor and the transmembrane membrane 
carrier work independently or together. In order to develop improved 
chemotherapeutic reagents and delivery strategies, it is essential to understand 
the folate uptake mechanisms in greater detail. 
Short oligonucleotides whch are designed to bind RNA or DNA (antisense 
oligonucleotides) as well as to inhibit specific enzymes or receptors have been 
developed for therapeutic applications (reviews 12a-c) . Oligonucleotides are 
relatively large negatively charged molecules and their delivery into a cell is 
limited by the presence of the cell plasma membrane. Many methods have been 
developed for the delivery of oligonucleotides into the cell cytoplasm (review 
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12b, see Introduction section in Chapter 3) and there are some reports which 
have demonstrated the effects of oligonucleotides or large DNA molecules in the 
cell nucleus (13). However, it remains to be determined how oligonucleotides 
can reach a cellular nucleus from the cellular cytoplasm if the oligonucleotides 
designed to interact with DNA, nuclear RNA, or nuclear proteins are delivered 
into the cellular cytoplasm by currently available delivery methods. The cell 
nucleus has a nuclear pore complex through which large nuclear proteins are 
recognized and transported into nucleus (reviews 14a-g). It is not clear whether 
oligonucleotides can enter a cellular nucleus through the nuclear pore complex 
or gain access to genomic DNA during mitosis when the nuclear membranes 
disappear temporarily (Fig. 7, ref. 4c). Nuclear proteins have nuclear localization 
signal peptides (14f) which are recognized by the nuclear pore complex. It is not 
clear whether these signal peptides could be used to enhance the uptake of 
oligonucleotides or to other therapeutic agents when the peptides are covalently 
conjugated to them. 
In this thesis the roles of folate receptors and transmembrane carriers were 
examined in cultured human epodermoid carcinoma (KB) cells in order to 
determine how the folate receptors and membrane carriers work in the folate 
uptake into cells, focusing on the uptake of 5-methyltetrahydrofolate. Based 
upon our results, the possible mechanism of entry of folate-toxin (momordin) 
conjugates into the cellular cytoplasm by folate receptor-mediated endocytosis 
and the possibility of using the folate uptake pathway for drug delivery into the 
cell cytoplasm are discussed. In order to determine whether therapeutic agents 
such as oligonucleoties could reach the cellular nucleus from the cellular 
cytoplasm, the transport of oligonucleotides into cellular nuclei through the 
nuclear pore complex was examined in reconstituted cellular nuclei without 
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plasma membranes (15). The effect of nuclear localization signal peptides on the 
delivery of oligonucleotides into the cellular nuclei was also examined in order to 
see if conjugation of nuclear localization signal peptides could enhance the 
uptake of oligonucleotides by reconstituted nuclei. (see Chapter 3). 
THESIS ORGANIZATION 
Chapter 2. 
Current models of folate uptake pathways are examined in the Introduction 
section. The roles of the folate receptor and the membrane anion carrier in the 
uptake of 5-methyltetrahydrofolate were studied to determine which model is 
correct by measuring the effects of temperature and inhibitors such as folic acid, 
methotrexate and probenecid on the uptake of 5-methyltetrahydrofolate. The 
effects of folic acid and probenecid on the folate receptor-mediated endocytosis 
of 5-methyltetrahydrofolate and on the membrane carrier-mediated transport of 
5-methyltetrahydrofolate are examined in the Results section. Models 
compatible with the experimental rsults from this research are discussed in the 
Results and Discussion sections. The possibility of using the folate uptake 
pathway for the intracellular delivery of macromolecules are discussed in the 
Implications and Future research section. 
Chapter 3. 
A general background for antisense oligonucleotide therapeutics is 
discussed in the Introduction section. Methods for reconstitution of nuclei with 
functional nuclear membranes and for study of the kinetics of olignucleotide 
transport into cell nuclei are discussed in the Materials and Methods section. 
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Data on the movement of 20-mer oligonucleotides into cellular nuclei are 
presented in the Results section. The effect of nuclear localization signal peptides 
on the transport of oligonucleotides into the cellular nuclei is also presented in 
the Results section. Possible applications of signal peptides are discussed in the 
Discussion section and also in the Implications and Future Research section. 
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Fig. 1. Absorption of drugs into target cells 
Orel 













muscle Bnd skin 
11 







*This was adapted from Singer, S. J. and Nicolson, G. L. (1972) Science 175, 723. 
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Fig. 3. Schematic diagram of passive transport down an electrochemical 
gradient and active transport against an electrochemical gradient 
Small uncharged molecules can directly cross the lipid bilayer (free diffusion) . 
Charged molecules including small ions are transfered through protein channels 
or carrier proteins (facilitated diffusion). Passive diffusion or facilitated diffusion 
occurs spontaneously without spending energy. Active transport occurs against 
an electrochemical or concentration gradient and requires energy. Adapted from 
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Fig. 4. Schematic diagram of a cell showing endocytosis, the fusion of 
endocytic vesicles with primary lysosomes to form secondary lysosomes and 
membrane recycling. Most vesicles are thought to fuse with other vesicles in the 
cytoplasm before fusing with lysosomes (not shown in this figure) . The right-
hand side of the figure, shows the selective retrival of the endocytic membrane 
from the secondary lysosome and its direct return to the plasma membrane. This 
is only one possible pathway of retrieval. Alternatively, selectively retrieved 
endocytic membrane can fuse with other intracellular organelles such as Golgi 
apparatus. Adapted from Alberts et al. (Molecular biology of the cell, Garland 
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Fig. 6. Drug delivery via folate receptor-mediated endocytosis 
0 folate-conjugated liposomes or other drugs 
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Fig. 7. Possible mechanisms of delivery of oligonucleotides into the cell 
nucleus 
(a) Direct transport into nucleus through nuclear pore complexes by free 
diffusion or by active transport 
(b) Cell cycle-dependent delivery into nucleus 
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Chapter 2: The roles of folate receptor and an anion carrier 
in the intracellular transport of 5-methyltetrahydrofolate 
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SUMMARY The roles of the folate receptor and an anion carrier in the uptake 
of 5-methyltetrahydrofolate (5-MeH.tfolate) were studied in cultured human (KB) 
cells using radioactive 5-MeH.tfolate. Binding of the 5-MeH.tfolate was inhibited 
by folic acid, but not by probenecid, an anion carrier inhibitor. The 
internalization of 5-MeH4folate was inhibited by low temperature, folic acid, 
probenecid and methotrexate. Prolonged incubation of cells in the presence of 
high concentrations of probenecid appeared to inhibit endocytosis of folate-
receptors as well as the anion carrier. The Vmax and KM values for the carrier 
were 8.65 ± 0.55 pmol/min/mg cell protein and 3.74 ± 0.54JlM, respectively. The 
transport of 5-MeH4folate was competitively inhibited by folic acid, probenecid 
and methotrexate. The carrier dissociation constants for folic acid, probenecid 
and methotreate were 641 JlM, 2.23 mM and 13.8 JlM, respectively. Kinetic 
analysis suggests that 5-MeH.tfolate at physiological concentration is transported 
through an anion carrier with the characteristics of the reduced-folate carrier 
after 5-MeH.tfolate is endocytosed by folate receptors in KB cells. Our data with 
KB cells suggest that folate receptors and probenecid-sensitive carriers work in 
tandem to transport 5-MeH4folate to the cytoplasm of cells, based upon the 
assumption that 1 mM probenecid does not interfere with the acidification of the 
vesicle where the folate receptors are endocytosed. 
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INTRODUCTION 
Folate compounds Folates are a group of heterocyclic compounds based on 
the N-pteridin-6-ylmethyl-p-aminobenzoic acid skeleton, often conjugated with 
one or more L-glutamic acid units (1, Fig. 1). Reduced-folates such as 5-
methyltetrahydrofolate (5-MefLtfolate)l and 5-formyltetrahydrofolate serve as 
carriers of activated one-carbon units in various enzyme-catalyzed reactions such 
as the biosyntheses of methionine, serine, deoxythymidylic acid and purines (2). 
Mammals obtain folates from their diets or from microorganisms since they are 
unable to synthesize a pterine ring. Membrane transport of folate compounds in 
mammalian cells has been the subject of intensive studies which have provided 
evidence for the existence of several transport mechanisms for folate (and 
antifolate) compounds (reviews 3-6, see Table 1). 
Transport systems for folate and methotrexate influx 
High affinity/low capacity transport system (the reduced-folate carrier) in 
L1210 cells The reduced-folate carrier (7-11), an anion carrier, has been shown to 
mediate the uptake of folate compounds such as 5-metyltetrahydrofolate (5-
MefLtfolate) (9), 5-formyltetrahydrofolate (12), folic acid (9,13) and an antifolate 
compound methotrexate (7-11) by extensive studies with L1210 mouse leukemia 
cells (7-13) and CCRF-CEM human lymphoblastic cells (14). This system has a 
greater preference for transport of reduced-folates such as 5-
methyltetrahydrofolate than oxidized folate such as folic acid (3). This system is 
inactivated by carbodiimide..:activated methotrexate (15) or N-
hydroxysuccinimide ester of methotrexate (16) and sulfhydryl modifying 
reagents such as p-chloromercuribenzene sulfonate (pCMBS, refs 17,18) and N-
ethylmaleimide (18). The uptake of folate compounds by the reduced-folate 
carier is competitively inhibited by various anions such as p-
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[dipropy1su1famoyl]benzoic acid (probenecid, 19, see Fig. 1), phosphate and 
sulfate (20) as well as folate compounds (4). It has been suggested that the 
reduced-folate carrier mediates the uptake of folates via an anion-exchange 
me.chanism (10, 21-24). A few of the characteristics of this transmembrane carrier 
(4) include: (a) high affinity for 5-substituted reduced folates (Michaelis-constant 
KM of 1- 3 ~M) and low affinity for folic acid (KM of 200-400 ~M); (b) a Vmax 
of 1 - 12 nmol/min/g dry cell; (c) high dependence on temperature, pH and 
energy; (d) trans-stimulation (10), i.e., stimulation of influx (or efflux) of one 
folate compound by the presence of a second folate compound inside (or outside) 
of cells. The use of derivatives of methotrexate to label covalently the carrier 
responsible for mediating reduced-folate transport in L1210 cells identified a 
single polypeptide with a molecular weight 43000 Dalton (25-28). The gene 
coding for this protein has not been isolated yet and the amino acid sequence for 
this protein is not known either. The reduced-folate carrier-mediated transport 
system has not been shown definitely to occur in any normal cells (3) . 
Low affinity/high capacity transport system in L1210 cells While the influx 
of folic acid is mediated in small part by the reduced-folate carrier, its transport is 
believed to occur predominantly by mechanism(s) which are distinct from this 
route (29, 30). This conclusion is based upon several observations by Sirotnak et 
al. (29, 30) . First, data showed that the Vmax for initial mediated influx of folic 
acid was much greater than that shown for initial influx of methotrexate and 
reduced-folates (29). The initial influx of both L-formyl-tetrahydrofolate and 
methotrexate was highly saturable (apparent KM=3-4 (±0.6) ~M) but exhibited a 
relatively low apparent Vmax 3 (±0.4) pmol/min/mg membrane protein. 
However, initial influx of folic acid exhibited low saturability (KM=409 (±66) ~M) 
and a high Vmax (123 (±33) pmol/min/mg membrane protein). Secondly, there 
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were major discordances between values for influx KM and influx Ki (inhibitor 
dissociation constant for a carrier) for various folate compounds. For compounds 
which share a single transport system, valus for influx KM and influx Ki for 
competition experiments should be approximately the same (29). The results 
show that this was not the case. Ki values of 5-formyltetrahydro-folate, 5-
methyltetrahydrofolate and methotrexate for folic acid uptake were much larger 
(greater than 1000 IJ.M) than the corresponding KM values. On the other hand, 5-
formyltetrahydrofolate, 5-m~thyltetrahydrofolate and methotrexate were very 
efficient competitive inhibitors for the uptake of radioactive 5-
formyltetrahydrofolate whereas folic acid was a poor competitive inhibitor of 5-
formyltetrahydrofolate uptake (Ki values were 1.82 (±0.9), 1.25 (±0.1), 4.56 (±0.6) 
and 442.0 (±72) IJ.M for 5-formyltetrahydrofolate, 5-Methyltetrahydrofolate and 
methotrexate and folic acid, respectively). Thirdly, the uptakes of 5-
formyltetrahydrofolate and methotreaxte were much more sensitive than that of 
folic acid to sulfhyfryl inhibitors (27). Additionally, the uptake of reduced-folates 
into the vesicle also showed trans-stimulation by the presence of a folate 
compounds inside the vesicle. Trans-stimulation was not observed for folic acid 
uptake. Finally, the time-course for intravesicular accumulation of 5-
formyltetrahydrofoalte and folic acid by plasma membrane vesicles isolated from 
wild-type (methotrexate-sensitive) and mutant (methotrexate-resistant) L1210 
cells showed additional evidence for the multuplicity of folate entry routes in 
L1210 cells (29, 30). The initial accumulation of 5-formyltetrahydrofolate was 
lower in mutant-derived vesicles than in the wild-type. However, initial 
accumulation of folic acid was the same in mutant and wild-type-derived 
vesicles. Therefore, it was proposed that folic acid influx in L1210 cells is 
mediated mainly by a system distinct from the classical reduced-folate carrier 
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mediating influx of methotrexate and folate compounds (29, 30) . This new 
system is called the low affinity /high capacity transport system (30) . The 
existence of this system is however, controversial and some researchers attribute 
the existence of this system to a phenomena caused by the impurities in the [3H]-
folic acid used in the experiments (31). This system has not been purified and 
nothing is known about its nature at molecular level. 
A secondary low capacity system in L1210 cells Henderson and Strauss 
(31) examined L1210/R81 cells to determine the mechanism by which 
methotrexate-resistant cells with a defect in methotrexate transport can achieve 
folate sufficiency. This cell-line lacked the reduced-folate carrier and the high-
affinity folate binding protein. The high affinity-folate binding protein (folate 
receptor), which is explained below, can mediate the uptake of folate at 
nanomolar concentration. Their results showed that an alternative transport 
system is operating in the L1210 variant cell line, which is manifested at low pH 
and mediates the energy-dependent influx of folate, 5-formyltetrahydrofolate, 
and methotrexate in the 5-10 !J.M range. This system binds but does not transport 
5-methyltetrahydrofolate. This system was not sensitive to the anion 
compositions in the transport assay buffer in contrast to the reduced folate 
carrier. This system was very sensitive to pH whereas the reduced-folate carrier 
was not. N-hydroxysuccinimide ester of methotrexate or bromosulfopthalein, 
the inhibitors for reduced-folate carrier did not have any effect on this system. 
In this cell line, the low affinity /high capacity system was not detected. 
Therefore, Henderson and Strauss (31) attributed the existence of the low 
affinity /high capacity system claimed by Sirotnak et al. (29, 30) to impurities in 
[3H]-folate. 
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High affinity folate binding proteins (folate receptors) in KB cells and 
L1210 cells 
Meanwhile, the membrane-bound folate receptors (32-48) have been shown 
to mediate the uptake of folate compounds such as 5-methyltetrahydrofolate (33) 
and methotrexate (34, 35) mainly by the studies with human nasopharyngeal 
carcinoma (KB) cells. The folate receptor has a greater affinity for folic acid 
(association constant Ka= 1.3 nM-1 , ref. 36) than for reduced-folates (Ka= 0.3 
nM-1 for 5-methyltetrahydrofolate, ref. 36). The folate receptor is bound to the 
cell surface through a glycosyl-phosphatidylinisitollinker (37-39, Fig. 1). It has 
been shown that the folate receptor recycles between the cell surface and an as 
yet undetermined intracellular location and it has therefore been suggested that 
the folate compounds in KB cells are endocytosed by the folate receptors (34). It 
has also been shown that the folate receptors are converted to soluble form by 
metaloprotease(s) and released into culture medium in the presence of high 
concentration of folates (40-42). The complementary DNA coding for the folate 
receptor in KB cells has been isolated (43) and the complete amino acid sequence 
(257 amino acid residues) of the folate receptor is known (44-47). The folate 
receptor is heavily glycosylated (48) and bound to the cell surface through a 
glycosyl-phosphatidylinisitol linker (37). A role for the reduced-folate carrier, 
the low affinity /high capacity system, or the secondary low capacity system for 
the transport of folate compounds has not been investigated in KB cells (3). 
Recent studies (6, 49-52) have shown that propagation of the L1210 cells (6, 
49-50, 52) or CCRF-CEM cells, a human leukemic cell line (51) in media 
containing only nanomolar concentrations of folate leads to the gradual 
expression of a high affinity folate binding protein as well as the reduced-fola te 
carrier, while cells grown in media containing micromolar concentrations of 
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folate expressed only reduced-folate carrier. It has been shown that this high 
affinity folate binding protein mediates the uptake of folic acid (36, 38). The folate 
binding protein in L1210 cells has amino-acid sequence homology to the folate 
receptor in KB cells and other sources (6), suggesting that it is a folate receptor. 
Analysis by polyacrylamide gel-electrophoresis has shown that the folate 
receptor and the reduced-folate carrier in L1210 cells have molecular weights 39 
and 43 kDa, respectively (27). It has been suggested that the folate binding 
protein and the reduced-folate carrier in L1210 cells operate independently to 
take up folate compounds (52). 
Folate receptor and an anion carrier in MA104 cells Recent studies (53-58) 
with cultured monkey kidney cells (MA104) have suggested that the uptake of 5-
methyltetrahydrofolate is mediated by both the folate receptor (53, 54) and an 
anion carrier with characteristics of the reduced-folate carrier (55, see Fig. 2 A). It 
has been shown that the folate receptor is bound to the extracellular surface of 
the nonclathrin-coated invaginated regions of the plasma membrane (caveolae, 
ref. 56) through a glycosylphosphatidyl inositol linker (57) . The caveolae can 
transiently close in MA104 cells to form vesicles (58) . It has also been shown that 
the uptake of 5-methyltetrahydrofolate is mediated by an anion carrier which is 
impaired by probenecid and has the kinetic parameters (KM and V max) similar 
to those of the reduced-folate carrier (55). Therefore it has been suggested that 
the probenecid-sensitive anion carrier and the membrane-bound folate receptor 
associated with caveolae work in tandem to transport 5-methyltetrahydrofolate 
to the cytoplasm as described in Fig. 2 A (5, 54-56). However, in these studies 
direct evidence that shows the coupling of the two systems has not been 
presented (3) . Therefore, the possibility that the folate receptor and the 
probenecid sensitive-carrier worked independently to transport 5-
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methyltetrahydrofolate can not be excluded (3, see Fig. 2 B). Moreover, it was 
not clearly shown whether this probenecid-sensitive anion carrier was exactly the 
same as the reduced-folate carrier or not (55). According to the studies by 
Henderson et al. (19), probenecid inhibits the influx and efflux of folate 
compounds through the reduced-folate carrier. Probenecid also inhibits the 
transport of sulfate (19). Sulfate is transported via both the reduced-folate-carrier 
and a general anion carrier (20). One of the primary functions of the general 
anion carrier is to exchange rapidly intracellular bicarbonate for extracellular 
chloride (20). Therefore, inhibition of 5-methyltetrahydrofolate uptake by 
probenecid does not necessarily mean that the reduced-folate carrier is the only 
system responsible for the 5-methyltetrahydrofolate uptake in MA104 cells. It is 
equally possible that the general anion carrier mediates 5-
methyltetrahydrofolate uptake in MA104 cells. This issue was not clarified in 
MA104 cells (55). Sulfate inhibits the uptake of methotrexate, but methotrexate 
hardly inhibits the sulfate transport in L1210 cells (20). If 5-
methyltetrahydrofolate transport occurs by the general anion carrier as sulfate 
transport does, it should not be inhibited by methotrexate. However, inhibition 
of 5-methyltetrahydrofolate by methotrexate has not been reported in those 
studies (55). Finally, the concentrations of the probenecid in those studies were 
too high (10 mM) and the effect of this inhibitor on other cellular processes such 
as endocytosis of folate receptor was not studied (55). Probenecid is known to 
slightly affect the ATP level, membrane potential and glucose utilization in the 
cell, suggesting that it is a weak metabolic inhibitor (19). 
Membrane carriers involved in methotrexate efflux Based upon kinetic 
analysis Dembo and Sirotnak (59, 60) proposed a model in which the influx and 
efflux of methotrexate take place via different carriers in L1210 cells. According 
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to this model, cells have a distinct influx carrier and efflux carrier (60). The efflux 
carrier is coupled to energy and it carries methotrexate unidirectionally out of the 
cell at the direct expense of ATP (61). But the influx carrier, the reduced-folate 
carrier is indirectly coupled to energy. According to them, return of the 
unloaded influx carrier from the inner to the outer side of the cell membrane 
could be accelerated by an elevated intracellular concentration of a specific 
competitive counter ion (perhaps one of the naturally occuring folates or even 
some kind of simple organ~c anions) . Alternatively, it is hypothesized that 
accelerated cycling of free carrier could be mediated by a mechanism based on 
nonspecific differences in the pH or ionic strength of the interior and exterior 
cellular compartments. Henderson et al. (11) reported that there are at least three 
routes for methotrexate efflux in cells (Table 2). The major efflux of this drug 
occurred through the reduced-folate carrier, which can be shown by the 
reduction in efflux in cells treated with the N-hydroxysuccinimide ester of 
methotrexate. A second route was identified by the sensitivity to 
bromosulfophthalein and insensitivity to N-hydroxysuccinimide ester of 
methotrexate. A third route was identified by the insensitivity to both reagents. 
All three efflux routes were inhibited by probenecid (19) . However, recent 
studies by Sirotnak et al. (62) showed that L1210 cells have only two efflux 
routes; the influx carrier and the bromosulfophthalein-, probenecid-, and 
verapamil-inhibitable efflux route. The existence of the third efflux route 
suggested by Henderson et al. (11) was denied by Sirotnak et al. (62) since no 
evidence was obtained for the third bromosulfophthalein-insensitive, 
probenecid-inhibitable route for methotrexate efflux in their experiments. The 
ATP-dependent, bromosulfophthalein-, probenecid-, and verapamil-inhibitable 
efflux route accounted for 90 % of methotrexate efflux in ATP-replete cells 
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whereas in ATP depleted cells overall efflux of methotrexate was markedly 
reduced and appeared to be mediated solely by the methotrexate influx carrier. 
It has not been clearly understood whether 5-methyltetahydrofolate uses the 
same efflux routes as suggested in the above model in L1210, KB or MA104 cells 
partly because the 5-methyltetrahydrofolate is rapidly metabolized inside the 
cells. 
Purpose of this study Various systems in the transport of folate 
compounds in mammalian cells were briefly reviewed above. Many issues 
remain to be resolved in these systems. Especially, the inter-relationship betwen 
the folate receptor, the probenecid-sensitive anion carrier and the reduced-folate 
carrier in the intracellular transport of 5-methyltetrahydrofolate and other folate 
compounds in eukaryotic cells has not been clearly understood (3). In order to 
determine whether the folate receptor and the probenecid-sensitive anion carrier 
work in tandem for the uptake of 5-methyltetrahydrofolate as suggested by the 
studies in MA104 cells (55, see Fig. 17 B), or independently as suggested by 
others (52, see Fig. 17 A), and to determine the identity of the probenecid-
sensitive anion carrier, we have studied the effects of folic acid and probenecid 
on various steps of 5-methyltetrahydrofolate uptake in KB cells. 
We report evidence here for 5-methyltetrahydrofolate uptake by a 
probenecid-sensitive anion carrier as well as the folate receptor in KB cells. Our 
data suggest that probenecid at very high concentration (5 mM) inhibits the 
endocytosis of the folate receptor as well as the anion carrier. Our data also show 
that the uptake of 5-methyltetrahydrofolate in KB cells is competitively inhibited 
by probenecid, folic acid and methotrexate, suggesting that the uptake is 
mediated by an anion carrier with the characteristics of the reduced-folate carrier. 
Finally, our data show that the occupancy of folate receptor by 5-
29 
methyltetrahydrofolate appears to enhance the transport of the vitamin through 
the probenecid-sensitive carrier, assuming that probenecid does not interfere 
with the acidification of the lumen of the endosomes (possibly caveola). 
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MATERIALS AND METHODS 
Materials 
Human epidermoid carcinoma (KB) cells (passage No.: 364) were obtained 
from American Type Culture Collection, Rockville, MD. Media constituents 
were obtained from Gibco Laboratories. Vitamins were purchased from Sigma 
Chemical Company. Fetal calf serum (FCS) was purchased from HyClone 
Laboratories, Inc., Logan, Utah. Fungi-Bact solution (penicillin G 10,000 
units/ml, streptomycin sulfate 10,000 ~J.g/ml, fungizone 25 11-g/ml in normal 
saline) were obtained from Irvine Scientific, Santa Ana, CA. (6S)-5-
methyltetrahydro[3', 5', 7, 9-3H]pteroylglutamate ([3H]-5-methyltetrahydrofolate) 
and [3', 5', 7, 9-3H]-folic ([3H]-folic acid) acid were purchased from Moravek 
Biochemicals, Brea, CA. o L -5-meth yl-tetrah ydrofola te ( o L- 5-
methyltetrahydrofolate, disodium salt), p-[dipropylsulfamoyl]benzoic acid 
(probenecid), bovine serum albumin (BSA, fraction V, Cat. No A-4378) and 
vitamins were obtained from Sigma Chemical Company. 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) was 
purchased from Aldrich Chemical Company, Inc., Milwaukee, Wisconsin. 
N a 125I was purchased from Amersham Corporation, Arlington Heights, IL. 
Iodo-beads were purchased from Pierce Chemical Company, Rockford, IL. 
Centriprep-30 concentrators were purchased from Amicon, Danvers, MA. 
Preparation of cell culture media (a) Folate-deficient Dulbecco's modified 
Eagle's medium (jdDMEM) and folate-deficient Dulbecco's modified Eagle's medium 
supplemented with 5 % fetal calf serum (fdDMEM, 5% FCS) : Folate-deficient 
Dulbecco's modified Eagle's medium (fdDMEM) was required to enhance the 
expression of folate rceptors in KB cells (32, 63). fdDMEM which has the same 
amounts of the media components as Dulbecco's modified Eagle's medium 
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(Gibco Laboratories manual) except for folic acid was formulated as follows (see 
Appendix A); For 1 liter medium, Earle's Balanced salt solution (powder, 1 
pkg./L), 40 ml basal medium Eagle supplements (amino acid solution), 21 ml 
HEPES (1.0 M), 10 ml MEM sodium pyruvate solution (100 mM), 20 ml L-
glutamine solution (200 mM), 10 111 ferric nitrate solution (Fe(N03)3.9H20, 10 
mg/ml), 0.3 ml glycine solution (100 mg/ml), 4.2 ml L-serine solution (10 
mg/ml), 2.2 g NaHC03, 10 ml Fungi-Bact solution and 40 ml vitamin stock 
solution made in the laboratory (100 mg/ml o-Ca panthothenate, 100 mg/ml 
choline chloride, 200 mg/ml i-inositol, 100 mg/ml nicotinamide, 100 mg/ml 
pyridoxal ·HCl, 10 mg/ml rivoflavin, and 100 mg/ml thiamine·HCI) were 
mixed. The volume of the solution was adjusted to about 900 ml with deionized 
water and the pH was adjusted to 7.3 with NaOH solution. For assay medium 
(fdDMEM), the final volume was adjusted to 1 liter. For cell culture medium 
(fdDMEM, 5% FCS), the final volume was adjusted to 1 liter after adding 50 ml 
heat-inactivated fetal calf serum. Since fetal calf serum contains almost 20 nM 
folate (32), the final folate content in fdDMEM, 5% FCS is estimated to be a 
maximum of 1 nM. 
(b) Minimum essential medium, 10 % fetal calf serum(MEM, 10 % FCS) : 
Minimum essential medium was prepared as described by the vendor and 
supplemented with 10 % (vol/vol) heat-inactivated fetal calf serum, penicillin 
(100 units/ml), streptomycin (100 IJ.g/ml) and fungizone (0.25 IJ.g/ml). This 
medium contains about 2.3 11M folic acid. All media were sterilized by filtering 
through 0.21J.m filter units and kept at 4 °C. 
Cell culture Cultures of KB cells were initiated as described by the 
supplier. 7x1QS KB cells were inoculated into 15 ml MEM, 10 % FCS in 75 cm2 
culture flasks and grown as a monolayor at 37 °C in a 5 % C02/95 % air 
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humidified atmosphere. The supernatant medium with cryopreservative was 
removed and fresh medium added to the cells after 24 hours culture. Cells were 
passed into fresh medium every 7 days using 0.25 % trypsin-1mM EDTA 
solution. 3 days after each passage, the medium was replaced with fresh 
medium. For 5-methyltetrahydrofolate uptake assays, cells were transferred 
for two consecutive passages into fdDMEM, 5% FCS to enhance the expression 
of folate receptors and the uptake of folates according to modified procedures of 
Leamon et al. (63); On day 0, _about 5x105 cells were passed into 15 ml fdDMEM, 
5% FCS and propagated as described above in 75 cm2 culture flasks. On day 6, 
cells were harvested and transferred into 6-well culture trays. 1.5x105 cells were 
seeded into each well containing 3 ml fdDMEM, 5 % FCS and cultured for 4 
days. The cells were used for uptake assays on day 10. 
Modification of proteins (a) Conjugation of DL-5-methyltetrahydrofolate to 
bovine serum albumin: DL-5-methyltetrahydrofolate was conjugated to bovine 
serum albumin (BSA) by the modified procedures of Leamon et al. (63). 5-
methyltetrahydrofolate solution (0.15 ml of 0.1 M) was prepared by mixing 0.125 
ml of 0.127 M S-methyltetrahydrofolateNa2 in DMSO and 0.025 ml 1 N HCl. 1-
(3-dimeth y laminopropy 1)-3-eth ylcarbodiimide hydrochloride (EDC · H Cl) 
solution (1 ml of 0.3 M in dimethylsulfoxide, DMSO) was added to 5-
methyltetrahydrofolate solution and the carboxyl groups of 5-
methyltetrahydrofolate were activated for 15 min at room temperature (23 °C). 
The 5-methyltetrahydrofolate/EDCHCl solution was added to 3 ml of 10 mg/ml 
BSA in PBS solution dropwise. After reaction for 5-6 hours, BSA which was 
covalently conjugated with 5-methyltetahydrofolates was purified by three 
consecutive gel filtrations; twice on a Sephadex G-25 gel filtration column (2.5 x 
40 em) and once on a Sephadex G-100-120 column (2.5 x 47 em). PBS (pH 7.4) 
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was used as an elution buffer. For the second and third gel filtration, eluted 
protein fractions were pooled and concentrated by centrifugation at 3,000 rpm 
for an hour in a GSA rotor (Beckman) using a Centriprep-30 concentration device 
(Amicon). After the third filtration, eluted protein fractions were collected and 
kept at -20 o C. 
(b) Conjugation of folic acid to bovine serum albumin: Folic acid was 
conjugated to bovine serum albumin (BSA) by the modified procedures of 
Leamon et al. (63). Folic acid in DMSO (1.25 ml of 0.02M) was added to 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCHCl) solution 
(1.127 ml of 0.3 Min DMSO) and the carboxyl groups of folic acid were activated 
for 15 min at room temperature (23 °C). The folic acid/EDCHCl solution was 
added to BSA in PBS solution (10 ml of lOmg/ml solution) dropwise. The 
reaction mixture was incubated at room temperature for 4 hours and purified as 
described above using gel filtration chromatography. 
(c) Characterization of the folate-conjugated BSA: Protein concentrations were 
determined using the Bio-Rad protein assay solution with BSA as a standard. 
The extent of DL-5-methyltetrahydrofolate conjugation to BSA was determined 
spectrophotometrically by measuring the absorbance of the conjugated protein at 
300 nm in lx PBS (pH 7.4) with DL-5-methyltetrahydrofolate as a standard. 350 
nm was used for folic acid. The absorbance of the conjugated protein was 
subtracted from the absorbance of free BSA at the same concentration. 
(d) Radioiodination of proteins: BSA and 5-methyltetrahydrofolate-conjugated 
BSA (mfBSA) were labelled with 125I using Iodo-beads at room temperature 
(23°C) for 45 minutes as described by the supplier (see Appendix B). 
Radioiodinated proteins were purified on Sephadex G-25 gel filtration columns 
(1.5x35 em) pre-equilibrated with 50 mM Tris-HCl(pH 7.5). y-Ray emissions were 
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measured on a Beckman Biogamma II counter for 20 ~1 aliquots from each 4 ml 
fractions . Protein concentrations of the radioiodinated proteins were 
determined using the Bio-Rad protein assay solution with BSA as a standard. 
Specific radioactivities of the iodinated proteins were determined by liquid 
scintillation counting using a Beckman LS 6800 scintillation counter. 
Binding and uptake assay The effects of folic acid and probenecid on the 
uptake of 5-methyltetrahydrofolate and 5-methyltetrahydrofolate-BSA conjugate 
were investigated according to modified procedures described by Kamen et al. 
(64) and Leamon et al. (63). On day 10 of cell growth in low-folate medium, the 
medium was removed by aspiration and 1 ml fresh fdDMEM was used to wash 
the cells. To measure the uptake of [3H]-5-methyltetrahydrofolate or 5-
methyltetrahydrofolate-BSA conjugate, appropriate amounts of [3H]-5-
methyltetrahydrofolate or 5-methyltetrahydrofolate-BSA in fdDMEM were 
added to the medium to desired concentrations in 1 ml final volumes. Cells 
were incubated for various lengths of time at 0 or 37 °C (64). At the end of the 
incubation, cells were chilled on ice immediately and the supernatants were 
collected by aspiration. After rinsing cells three times with 1 ml ice-cold 
Dulbecco's phosphate buffered saline (DPBS), cell-surface bound [3H]-5-
methyltetrahydrofolate or radioiodinated 5-methyltetrahydrofolate-BSA 
conjugate was released from the cells by washing rapidly for 30 seconds with 2 
ml ice-cold acid saline (0.15 M NaCl, adjusted to pH 3 with glacial acetic acid, 
twice with 1 ml saline solution where indicated) followed by a rinse with 1 ml 
cold DPBS. The radiolabelled folate or 5-methyltetrahydrofolate-BSA conjugate 
in the acid saline was combined with 1 ml cold DPBS wash to represent [3H]-5-
methyltetrahydrofolate or 5-me thyltetrahydrofolate-BSA conjugate released 
from the cell surface receptors by acid wash (acid-dissociable fractions). The cells 
35 
were detached from the culture dish by incubating the cells in 1 ml 0.25 % 
trypsin-1 mM EDTA for 5 min at 37°C and the flask was rinsed twice with 1 ml 
DPBS. The trypsin-EDT A cell suspension and DPBS washes were combined and 
represent [3H] -5-methy ltetrah ydrofola tes, or 5-meth yltetrah ydrofolate-BSA 
conjugates that are internalized by cells (acid-resistant fractions). Alternatively, 
cells were solubilized in 1 ml of 1% SDS, 0.1 N NaOH solution and the flask was 
rinsed twice with 1 ml DPBS. The amount of [3H]-5-methyltetrahydrofolate was 
measured by counting in duplicate 0.1 ml aliquots of the incubation media and 1 
ml aliquots of acid-dissociable and acid-resistant fractions in sciltillation fluid, 
Safety Solve with a Beckman LS 6800 scintillation counter. The amount of [3H]-5-
methyltetrahydrofolate or 5-methyltetrahydrofolate-BSA conjugate was 
quantitated using a specific activity value taken from the slope of a standard 
curve for the radioactivity versus the amount of [3H]-5-methyltetrahydrofolate or 
5-methyltetrahydrofolate-BSA conjugate. The protein content for each of the 
trypsin-EDT A cell suspensions was determined using 0.1 ml aliquots in duplicate 
by Peterson's modified Lowry method (65, see Appendix C) with bovine serum 
albumin as a standard. The amount of trypsin in the suspension, which was 
determined separately, was subtracted from the protein content of the trypsin-
EDTA cell suspension. In order to determine the average mass of a KB cell, cells 




Cooperative binding of 5-methyltetrahydrofolate to the folate receptor in 
KB cells We measured the amount of 5-methyltetrahydrofolate associated with 
the cell or media after incubation of the cells in the presence of varying 
concentrations of [3H]-5-methyltetrahydrofolate for 4 hours at 0 oc (Fig. 3 A). 
The internalization of 5-methyltetrahydrofolate was negligible at 0 oc. Most of 
the cell-associated vitamin was in the acid-dissociable fraction. This shows that 
5-methyltetrahydrofolate can bind to the cell surface but can not be internalized 
by the cells at 0°C. In order to determine whether the folate receptors bind 5-
methyltetrahydrofolate cooperatively or not, the data partly shown in Fig. 3 A 
were analysed by a Scatchard plot (66) . In the analysis, it was assumed that a cell 
is a macromolecule containing multiple binding sites for 5-
methyltetrahydrofolate. The Scatchard plot (Fig. 3 B) showed that the binding of 
the 5-methyltetrahydrofolate to the cell is positively cooperative. It has been 
shown that the folate receptor has only one binding site per molecule (36). If the 
folate receptor exists as a monomer, binding of 5-methyltetrahydrofolate to a 
receptor would not be affected by the occupancy of a neighboring folate receptor. 
Therefore, our result suggests that the folate receptors exist as oligomers on the 
cell surface. Using fluorescent antibodies against folate receptors Rothberg et al. 
(56) have shown that the receptors are clustered on the cell surface. This result is 
consistent with our suggestion that the folate receptors exist as oligomers. The 
average number of binding sites on a KB cell was determined using a graph as 
shown in Fig. 3 C and D. The approximate number of binding sites per mg cell 
protein obtained from the extrapolation of graph (Fig. 3 C) was 135 pmol/mg cell 
protein, which corresponds to 44x 106 sites per cell (using 5.36xlo-7 mg as an 
average mass of KB cell). This is slightly smaller than the previously reported 
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value in KB cells (193 pmol/mg, ref. 32). This difference could be due to the 
maintenance of cells in different media. 
Inhibition of 5-methyltetrahydrofolate uptake by probenecid, folic acid 
and low temperature in KB cells We studied the effects of probenecid and 
temperature on the uptake of [3H]-5-methyltetrahydrofolate to define the role of 
the reduced-folate carrier in KB cells since it has already been shown that the cell 
surface-bound folate receptors are involved in the transport of [3H] -5-
methyltetrahydrofolate in KB cells (33). Our data show that probenecid inhibits 
the internalization of [3H]-5-methyltetrahydrofolate (Fig. 4 A and C, also see Fig. 
5 A) but does not influence the binding of the vitamin to the receptors 
significantly (Fig. 4 A, also see Fig. 5 B). The reason why the acid-dissociable 
fraction appears to increase as the concentration of probenecid increases in Fig. 4 
B is that as probenecid inhibits the uptake of the vitamin more, the concentration 
of the vitamin in the medium remains higher and more of the folate molecules 
are bound to cell surface. In order to see if the probenecid-sensitive uptake 
process is inhibited at low temperature, we measured the acid-resistant fractions 
and acid-dissociable fractions with or without 5 mM probenecid at 0 °C or 37 °C 
(Fig. 5 A and B). The results (Fig. 5 A) show that the uptake of 5-
methyltetrahydrofolate is inhibited by probenecid significantly at 37 °C and 
uptake is abolished at 0 °C, which is consistent with the previous results by 
others (55). Probenecid did not have any further inhibitory effect on the uptake 
of the vitamin at 0 °C. This indicates that the probenecid-inhibitable uptake 
process is sensitive to temperature. The data for acid-dissociable fractions of 5-
methyltetrahydrofolate at 0 or 37 °C with or without 5 mM probenecid are 
shown in Fig. 5 B. At 0 °C the acid-dissociable fractions show a concentration 
dependent increase and saturation over 0.5 j.!M (Fig. 5 B). The maximum amount 
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of 5-methyltetrahydrofolate bound was about 70 pmol/mg cell protein, which is 
approximately a half of 135 pmol/mg cell, the maximum number of binding sites 
per mg cell obtained from Fig. 3D. This could be due to the assumption that 
only the L-isomer of 5-methyltetrahydrofolate is active in binding and 
internalization. These experimental results suggest that D-isomer can also bind 
to the folate receptor with almost identical affinity as the L-isomer. However, 
throughout the calculation in this work, we assumed that only the L-isomer can 
bind and be internalized by the cells. 
Interestingly, at 37 °C the acid-dissociable fractions increase in a 
concentration-dependent manner below 0.2 J.lM and decreases above 0.2 J.lM and 
does not change much above 1 J.l M (Fig. 5 B). Above 1 J.l M 5-
methyltetrahydrofolate the amount of the acid-dissociable fraction at 37 °C is 
approximately one-third of that at 0 °C. Probenecid does not have any 
significant effect on the acid-dissociable fractions at both 0 oc and 37 °C, which is 
consistent with the results shown in Fig. 4 A. This indicates that the factor that 
changes the number of 5-methyltetrahydrofolate binding proteins on the cell 
surface is not probenecid. It has been reported that folate-receptors are down-
regulated in the cells grown in media containing high concentrations of 5-
methyltetrahydrofolate (67). It has been also shown that the membrane-bound 
folate receptors are released into the medium by a membrane-associated 
metalloprotease in the presence of high concentration of folates (42). Therefore 
we suggest that the decrease in the acid-dissociable fractions over 0.5 J.lM 5-
methyltetrahydrofolate at 37 °C (Fig. 5 B) is the result of receptor down-
regulation which is sensitive to temperature and the concentration of 5-
methyltetrahydrofolate, but not to probenecid. Further studies would be 
required to verify this interpretation. 
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In order to define further the role of the probenecid-sensitive carrier and the 
folate receptors in the uptake of 5-methyltetrahydrofolate at physiological 
concentrations, we studied the effects of combinations of probenecid and folic 
acid on the uptake of [3H]-5-methyltetrahydrofolate by KB cells. Experimental 
results show that both folic acid and probenecid inhibit the uptake of 5-
methyltetrahydrofolate in KB cells (Fig. 6A and B). 100-fold excess of folic acid 
almost completely abolished the binding of 5-methyltetrahydrofolate to the cell. 
This shows that folic acid is a very efficient reagent for blocking the binding site 
of folate receptors on the cell surface. However, small amounts of 5-
nethyltetrahydrofolate were still taken up by the cells (Fig. 6B) even though 
almost all the folate receptors were blocked by folic acid (Fig. 6A). This small 
fraction of uptake could be further inhibited by probenecid (Fig. 6B). These 
results suggest that KB cells have a separate system which is different from the 
folate receptor for the uptake of 5-methyltetrahydrofolate. Summarizing the 
results of the above experiments, KB cells appear to have a probenecid-sensitive 
system as well as folate receptors for the internaliz ation of 5-
methyltetrahydrofolate. 
Folate receptor-dependent uptake of folate-BSA conjugates In order to 
determine whether the effect of probenecid on 5-methyltetrahydrofolate uptake 
was solely due to the inhibition of a putative anion carrier for 5-
methyltetrahydrofolate transport, we needed to measure the effect of probenecid 
on endocytosis of folate receptors. It has been shown that conjugation of folic 
acid to proteins enhanced the uptake of the proteins by KB cells (63). It has also 
been shown that folyl polyglutamates can not diffuse out of the cell through the 
probenecid anion carrier in MA104 cells (55). It has also been shown that a 
methotrexate derivative which was covalently linked to fluorescein isothiocynate 
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via a diaminopentyl spaced linker, was bound to, but was not transported by the 
reduced-folate carrier of L1210 cells over a period of a few hours (68). Therefore 
we reasoned that the functional diameter of the carrier would be small and the 5-
methylterahydrofolate-BSA conjugate would not translocate to the cytoplasm 
through the probenecid sensitive anion carrier and the uptake of the 5-
methylterahydrofolate-conjugated BSA would not be sensitive to probenecid. 
Therefore we measured the effect of probenecid on the uptake of the 5-
methylterahydrofolate-BSA conjugate in order to determine whether this reagent 
has any inhibitory effect on the endocytosis of folate receptors. 
Before we measured the effect of probenecid on the uptake of 5-
methyltetrahydrofolate-BSA, we determined whether the uptake of the vitamin-
BSA conjugate was folate receptor-dependent. Our data (Fig. 7 A) showed that 
covalent conjugation of the DL-5-methyltetrahydrofolate to BSA enhanced the 
uptake of BSA by KB cells. This result is consistent with the report by Leamon et 
al. (63). In order to determine whether this enhanced uptake was due to specific 
interactions between the folate receptors and the conjugated 5-
methyltetrahydrofolates, uptake assays were performed in the presence of 0-100 
Jl M D L -5-methyltetrahydrofolate. The average number of 5-
methylterahydrofolates conjugated to BSA was 10 (±1) and the concentration of 
5-methyltetrahydrofolate in 12 Jlg/ml 5-methyltetrahydrofolate-conjugated BSA 
solution corresponded to 1.8 (±0.2) JlM. Our data (Fig. 7 B) showed that the acid-
dissociable fractions, i.e., the binding of the 5-methyltetrahydrofolate-conjugated 
BSA to the receptors on the cell surface were reduced to background in the 
presence of excess free 5-methyltetrahydrofolate, indicating that the binding of 
the 5-methyltetra-hydrofolate-conjugated BSA is specific for folate receptors. On 
the contrary, the acid-resistant fractions of 5-methyltetrahydrofolate-conjugated 
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BSA were not completely reduced to background even in the presence of more 
than 50 times excess of 5-metyltetrahydrofolate. This background could be due 
to uptake by nonspecific interaction. Other data represented in Fig 7C showed 
that folate-BSA conjugate inhibited the uptake of [3H]-folic acid more than 98 %. 
Goldman (9) reported that the uptake of methotrexate in Ehrlich ascites tumor 
cells was reduced in the presence of human serum albumin. This was attributed 
to the electrostatic interaction between methotrexate and albumin. Our data in 
Fig. 7D showed that the inhibition of [3H]-folic acid uptake by folate-BSA 
conjugate shown in Fig. 7C was not soley due to albumin. The uptake of [3H]-5-
methyltetrahydrofolate at 90 nM was smaller in the presence of folate-BSA 
conjugate than in the presence of the same concentration of BSA (Fig. 7D). These 
results suggest that folate or 5-methyltetrahydrofolate conjugated BSA molecules 
bind to folate receptors and are endocytosed by KB cells. 
Inhibition of uptake of 5-methyltetrahydrofolate-BSA conjugate by 
prolonged incubation of KB cells in the presence of high concentrations of 
probenecid. The effect of probenecid on the uptake of 5-methyltetrahydrofolate-
BSA conjugates is shown in Figs. 8 and 9. In Fig. 8 A, probenecid appears to 
inhibit the uptake of the 5-methyltetrahydrofolate-BSA conjugate at low 
concentrations whereas at high concentrations the uptake appears to be slightly 
stimulated in the presence of probenecid. It is not clear whether this is due to 
experimental error or to some other effect. One possible reason for this will be 
discussed below. The inhibition of the uptake of the 5-methyltetrahydrofolate-
BSA conjugate by probenecid was more clearly shown in a time-dependent 
uptake experiment (Fig. 9 A and B). The inhibition of uptake was undetectable 
during the first 30 min and became pronounced after 2 hours Fig. 9 A. The 
uptake of 5-methyltetrahydrofolate-BSA conjugate appears slightly more in the 
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presence of 5 mM probenecid than in the absence of the inhibitor during the first 
30 min period in Fig. 9 B. As mentioned above, Goldman (9) reported that the 
uptake of methotrexate in Ehrlich ascites tumor cells was reduced in the presence 
of human serum albumin. This was attributed to the electrostatic interaction 
between methotrexate and albumin. Then, it is possible that 5-
methyltetrahydrofolate-BSA conjugates aggregate by charge-charge interactions, 
i.e., the electrostatic interaction between positively charged groups of 5-
methyltetrahydrofolate-BS~ conjugate and free carboxyl groups from the 
conjugated-folates. This would be possible since the conjugated BSA still 
contains many unmodified lysines as well as other positively charged groups. 
Then, the concentration of accessible 5-methyltetrahydrofolate in the 5-
methyltetrahydrofolate-BSA conjugate solution might be smaller than expected. 
In the presence of probenecid, however, the accessible concentration of 5-
methyltetrahydrofolate in the 5-methyltetrahydrofolate-BSA conjugate solution 
would be increased since the carboxyl group of probenecid could compete for 
positive charges with 5-methyltetrahydrofolate. This might be the reason why 
the uptake of 5-methyltetrahydrofolate-BSA conjugate appears slightly more in 
the presence of 5 mM probenecid than in the absence of the inhibitor during the 
first 30 min period in Fig. 9 B. Our data shown in Fig. 7 D support this argument. 
The uptake of [3H]-5-methyltetrahydrofolate in the presence of both BSA and 1 
mM probenecid is more than that in the presence of BSA only. This implies that 
the reduction of the free [3H]-5-methyltetrahyfrofolate concentration by BSA 
could be reversed by the addition of 1 mM probenecid. It is expected that 
probenecid should inhibit the uptake of [3H]-5-methyltetrahydrofolate even in 
the presence of BSA. Then, it is believed that the inhibition of [3H]-5-
methyltetrahydrofolate uptake by probenecid w as masked by a larger increase of 
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[3H]-5-methyltetrahydrofolate uptake due to a large increase of [3H]-5-
methyltetrahydrofolate concentration in the solution by probenecid. A similar 
situation could occur at high concentration of 5-methyltetrahydrofolate-BSA 
conjugate. The degree of aggregation of 5-methyltetrahydrofolate-BSA conjugate 
should depend on the total concentration of the added conjugate. It is expected 
that the average size of aggregates of 5-methyltetrahydrofolate-BSA conjugate 
would increase as the total concentration of 5-methyltetrahydrofolate-BSA 
conjugate increase. Then, the reversal effect of probenecid would appear greater 
as the total concentration of 5-methyltetrahydrofolate-BSA conjugate increases. 
If this is the case, the inhibition of 5-methyltetrahydrofolate-BSA uptake by 
probenecid could be masked by the increase in uptake due to a large increase of 
free 5-methyltetrahydrofolate-BSA conjugate in the solution by probenecid. This 
might be the reason why the uptake of 5-methyltetrahydrofolate-BSA conjugate 
appears slightly more in the presence of 5 mM probenecid than in the absence of 
the inhibitor over 10 11-g/ml region in Fig. 8 A. Further experiments are required 
to verify this. 
Summarizing the above results, the uptake of 5-methyltetrahydrofolate-BSA 
conjugate appears to be slightly slowed down by prolonged incubation of cells in 
the presence of 5 mM probenecid. As mentioned earlier, it has been shown that 
folyl polyglutamates can not diffuse out of the cell through the probenecid anion 
carrier in MA104 cells (55) and that methotrexate covalently linked to fluorescein 
isothiocynate via diaminopentyl spaced linker, bound to, but was not 
transported by the reduced-folate carrier of L1210 cells over a few hour period 
(68). This suggests that the functional diameter of the probenecid-sensitive 
carrier is not big enough for the translocation of folate-conjugated BSA through 
this carrier. This suggests that the inhibition of 5-methyltetrahydrofolate-BSA 
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uptake by probenecid is not due to the blocking of the probenecid-sensitive 
carrier by probenecid and suggests that probenecid inhibits folate receptor-
mediated endocytosis of 5-methyltetrahydrofolte-conjugated BSA in KB cells. 
Effect of short-term incubation of KB cells in varying concentrations of 
probenecid on the uptake of 5-methyltetrahydrofolate-BSA conjugate by KB 
cells. In order to see if the endocytosis of folate receptor is inhibited 
significantly by concentrations of probenecid lower than 5 mM, we measured 
the effect of 30 min-incubations at varying concentrations of probenecid on the 
uptake of 5-methyltetrahydrofolate-BSA conjugate. The results presented in Fig. 
10 show that incubation of cells in the presence of up to 1 mM probenecid for 30 
min does not significantly change the uptake of 5-methyltetrahydrofolate-BSA 
conjugate compared to the cells without probenecid treatment. 
Effect of probenecid on the kinetics of 5-methyltetrahydrofolate binding 
to folate receptor In order to verify that the decreased uptake of 5-
methyltetrahydrofolate-BSA is not due to simple inhibition of the binding of the 
5-methyltetrahydrofolate residues to folate receptors, we measured time-
dependent binding of 5-methyltetrahydrofolate to cells in the presence and 
absence of probenecid. The results shown in Fig. 11 suggested that the binding 
kinetics were not significantly altered by the presence of 1 mM probenecid. 
Time-dependent uptake of 5-methyltetrahydrofolate at micromolar 
concentrations by KB cells In order to study the kinetics of 5-
methyltetrahydrofolate uptake by the putative probenecid-sensitive anion 
carrier, time-dependent uptake by KB cells was measured at micromolar 
concentrations. The initial uptake of 5-methyltetrahydrofolate was very rapid 
and began to approach steady-state after a few minutes (Fig. 12). This uptake 
experiment was performed in the presence of 0.5 mM excess folic acid, under 
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conditions for which almost all the folate receptors should be saturated by folic 
acid (see Fig. 6 A). These results suggest that KB cells have a transport system for 
5-methyltetrahydrofolate which is distinct from the folate receptor. If this 
alternative system is a transmembrane anion carrier similar to the reduced-folate 
carrier in L1210 cells, the steady state of uptake could be explained by the rapid 
increase in the efflux of the 5-methyltetrahydrofolate. Similar experiments were 
done at 0 °C to make sure that the uptake was temperature-dependent. 
Scintillation counting of the samples for uptake at 0 oc gave values close to 
background (data not shown). This showed that the transport of the 5-
methyltetrahydrofolate was temperature-dependent. In order to see if the initial 
uptake of the 5-methyltetrahydrofolate increased linearly during the first few 
minutes, time-dependent uptake experiments were done at varying 
concentrations as shown in Fig. 13. Our data showed that the increase in the 
acid-resistant fraction was almost linear during the first 3 minutes. The effect of 
excess folic acid on the uptake of 5-methyltetrahydrofolate was also measured as 
shown in Fig. 14. Excess folic acid with a fixed concentration ratio to 5-
methyltetrahydrofolate inhibited the uptake of the 5-methyltetrahydrofolate 
slightly. A double-reciprocal (Lineweaver Burk) plot showed that the uptake of 
5-methyl-tetrahydrofolate by KB cells followed Michaelis-Menten kinetics. The 
double-reciprocal plots in the presence and absence of folic acid showed that the 
two curves have very similar slopes. This could be explained if folic acid acts as 
a competitive inhibitor for the 5-methyltetrahydrofolate carrier as described by 




_1_ + KM (1 + 1!1)_1 ............... (i) 
V max V max Ki (S] 
_!_ = ( 1 + KM _!_ J!l ) + KM _1 ... ( ii) 
V Vmax Vmax Ki (S] Vmax (S] 
where V, Vmax, KM, Ki, [I] and [S] are the rate of uptake, maximum rate of 
uptake, Michaelis constant of 5-methyltetrahydrofolate for the carrier, 
dissociation constant of the inhibitor to the carrier, concentration of inhibitor, 
folic acid and concentration of 5-methyltetrahydrofolate, respectively. Equation 
(i) which is the Michalis-Menten equation with the competitive inhibitor i at a 
concentration [I], can be rearranged as equation (ii) . Since the ratio [1]/[S] is 
fixed, the first term on the right-hand side of equation (ii) becomes a constant. 
Therefore the slope of curve 1/V against 1/[S] at [1]=0 is equal to that at non-zero 
[1]. 
Competitive inhibition of 5-methyltetrahydrofolate uptake by 
probenecid, folic acid and methotrexate. In order to characterize further the 
putative anion carrier for 5-methyltetrahydrofolate in KB cells, the effect of 
probenecid, folic acid and methotrexate on the transport of 5-
methyltetrahydrofolate was studied (Fig. 15). The data presented in Fig. 15 D, E 
and F showed that the uptake of 5-methyl-tetrahydrofolate in the presence and 
absence of probenecid, folic acid and methotrexate followed Michaelis-Menten 
kinetics. The average Vmax and KM values of 5-methyltetrahydrofolate for the 
carrier are 8.65 (± 0.55) pmol/min/mg cell protein and 3.74 (± 0.54) IJ.M, 
repectively. Least squares analysis of the lines in the Lineweaver Burk plots 
showed that the two lines in each figure intercept at points very close to they-
axis, suggesting that the transport of 5-methyltetrahydrofolate was competitively 
inhibited by folic acid, probenecid and methotrexate (Fig. 15 D, E and F). The 
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carrier dissociation constants for folic acid, probenecid and methotreate were 641 
).1M, 2.23 mM and 13.8 ).1M respectively. The KM and Ki values showed that the 
carrier has the highest affinity for 5-methyltetrahydrofolate followed by 
methotrexate, folic acid and probenecid. The fact that methotrexate was a 
competitive inhibitor for the uptake of 5-Methyltetrahydrofolate in KB cells has a 
very important implication. As discussed above, sulfate inhibits the uptake of 
methotrexate but methotrexate hardly inhibits the sulfate transport in L1210 cells 
(20). Sulfate was transported by both the general anion carrier and the reduced-
folate carrier whereas methotrexate was transported only by the reduced-folate 
carrier (20) . If 5-methyltetrahydrofolate was transported by the general anion 
carrier as sulfate was, it should not be inhibited significantly by methotrexate. 
Our data showed that the uptake of 5-methyltetrahydrofolate was indeed 
substantially inhibited by 30 ).1M methotrexate (Fig. 15 C and F). This was strong 
evidence that in KB cells 5-methyltetrahydrofolate was not transported by the 
general anion carrier, but by a specialized anion carrier with the characteristics of 
the reduced-folate carrier found in L1210 cells. 
Approximate rate of folate-receptor endocytosis In the analyses of uptake 
kinetics by Michaelis-Menten equations, we assumed that the uptake of 5-
methyltetrahydrofolate by folate receptor endocytosis was negligible. In order to 
see if this assumption was valid, we measured the rate of folate receptor 
endocytosis using the modified procedures of Kamen et al. (54). In this 
measurement, we assumed that the transport of folic acid via the reduced-folate 
carrier would be very small since folic acid has a very low affinity for the 
reduced-folate carrier. The aproximate value of the endocytosis rate was 
obtained by preincubating the cells in the presence of 100 nM [3H]-folic acid for 
4-6 hours at 0 °C to saturate the receptors without any uptake and by incubating 
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the cells at 37 °C for varying periods of time. Our data showed that (3H]-folic 
acid initially bound to the folate receptors moved into the cells as the cells were 
incubated at 37 oc (Fig. 16 A). It was also clear that a considerable amount of 
[3H]-folic acid was released into the incubation medium from the cell surface 
(Fig. 16 B). Therefore, the rate of [3H]-folic acid uptake would be only a lower 
limit for the true endocytosis rate. The uptake of [3H]-folic acid was almost 
linear for the first 15 minutes and began to slow down after that (Fig. 16 C and 
D). The initial rate of [3H]-folic acid uptake was 0.2 pmol/mg cell/min (Fig. 16 
D). The rates of 5-methyltetrahydrofolate uptake at micromolar concentrations 
was typically more than a few picomoles/min/mg cell protein (Fig. 14 A and Fig. 
15 A, B, and C). Therefore, we could assume that the error in the determination 
of true rate of 5-methyltetrahydrofolate by the reduced-folate carrier would not 
be significant under our experimental conditions. However, the fraction of 
uptake via endocytosis would be considerable at very low vitamin 
concentrations. More accurate kinetic parameters could be obtained by 
measuring the uptake rate in the presence of excess folic acid to reduce the 
uptake of 5-methyltetrahydrofolate by endocytosis. 
The interrelationship between the folate receptor and the reduced-folate 
carrier in intracellular 5-methyltetrahydrofolate uptake In order to define 
further the role of the probenecid-sensitive anion carrier and the folate receptors 
in the uptake of 5-methyltetrahydrofolate at physiological concentrations, we 
studied the effects of combinations of probenecid and folic acid on the uptake of 
[3H]-5-methyltetrahydrofolate by KB cells (see Fig. 17). We reasoned that the 
transport of 5-methyltetrahydrofolate through the probenecid-sensitive anion 
carrier would be enhanced by folate receptors if the folate receptor and the 
probenecid-sensitive carrier work in tandem as suggested by the studies with 
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MA104 cells (see Fig. 2 A and Fig. 17 B, ref. 55). On the contrary, if folate 
receptors and the reduced-folate carrier work independently, folate receptors 
would not enhance the uptake of 5-methyltetrahydrofolate through the 
probenecid-sensitive anion carrier (see Fig. 2 Band Fig. 17 A). 
In order to measure the transport of 5-methyltetrahydrofolate through the 
probenecid-sensitive anion carrier with, or without the participation of the folate 
receptor, we needed to inactivate selectively one of the two transport systems 
without disturbing the other significantly. We showed that probenecid does not 
interfere with binding of 5-methyltetrhydrofolates to the folate receptors 
significantly (Fig. 5 B and Fig. 11). We also showed that incubation of KB cells 
for 30 minutes in the presence of 1 mM probenecid does not interfere with 
endocytosis of folate receptors significantly (Fig. 10). If we make an additional 
assumption that probenecid does not significantly interfere with the acidification 
of the lumen of vesicles where the 5-methyltetrahydrofolate-folate receptor 
complexes are endocytosed and the 5-methyltetrahydrofolates are released from 
the receptors at low pH as proposed by others (54, 55), without interfering with 
folate receptors, we could measure the 5-methyltetrahydrofolate transport into 
the cell cytoplasm through the probenecid-sensitive anion carrier by taking the 
differences of [3H]-5-methyltetrahydrofolate uptake in the presence and absence 
of 1 mM probenecid (see explanations in Fig. 17). Meanwhile, if folic acid at 
micromolar concentrations could block the binding of 5-methyltetrahydrofolate 
at nanomolar concentrations to the receptors, the folate receptor-mediated 
uptake of 5-methyltetrahydrofolate at physiological concentrations could be 
inhibited selectively by folic acid without affecting the probenecid-sensitive 
carrier significantly. As shown in Fig. 6 A, 100-fold excess folic acid blocked the 
binding of [3H]-5-methyltetrahydrofolate almost completely. The transport of 
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the vitamin through the probenecid-sensitive carrier should not be inhibited 
significantly by folic acid since the Ki of folic acid for the carrier is very large (641 
J.!M). This can be shown by a simple calculation for the transport of 5-
methyltetrahydrofolate in the absence and presence of folic acid as an inhibitor 
using the Michaelis-Menten equation as follows; 
V = V max[S] . . .. . . ...... ... (iii) 
KM (1 + ~~ ) + [S] 
I 
where V, Vmax, KM, Ki, [I] and [S] are the rate of uptake, maximum rate of 
uptake, Michaelis constant of 5-Methyltetrahydrofolate, dissociation constant of 
folic acid to the carrier, concentration of folic acid and concentration of 5-
Methy}tetrahydrofolate, respectively. Our calculations showed that the expected 
amount of uptake of [3H]-5-methyltetrahydrofolate through the probenecid-
sensitive carrier at 50 nM in the absence and presence of 5J.1M folic acid would be 
0.114 and 0.113 pmol/mg cell/min, respectively. This showed that the inhibition 
of the carrier by folic acid would not be significant. In the presence of 1 mM 
probeneid, the inhibition by excess folic acid could be calculated using a 
Michaelis-Menten equation with two competitive inhibitors shown below; 
V = V max[S] .. . ............ (iv) 
KM (1 + lliJ + [l2 ] ) + [S] 
Kil Ki2 
where [11], [I2],Ki1 and Ki2 are the concentration of inhibitor 1, that of inhibitor 2, 
carrier dissociation constant of inhibitor 1 and that of inhibitor 2, respectively. 
For example, the transport of 5-methyltetrahydrofolate at 50 nM in the presence 
of 1 mM probenecid without and with 5 J.!M folic acid would be 0.0791 and 
0.0787 pmol/mg cell/min, respectively. Again the difference was very small. As 
shown by these calculations, the inhibition of the probenecid-sensitive carrier by 
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folic acid would not be very significant. Therefore, in the presence of excess folic 
acid, the [3H]-5-methyltetrahydrofolate transport into the cell cytoplasm through 
the probenecid-sensitive anion carrier without the function of folate receptors 
could be measured by taking the differences of [3H]-5-methyltetrahydrofolate 
uptake in the presence and absence of 1 mM probenecid (see explanations in Fig. 
17). In summary, these considerations suggest that the lower limits of the 
amounts of [3H]-5-methyltetrahydrofolate that are transported through the 
probenecid-sensitive carrier with and without the participation of the folate 
receptors could be measured selectively under the experimental conditions 
disscussed above. 
The results of such experiments are shown in Fig. 18 A and analysed in Fig. 
18 B. The amount of [3H]-5-methyltetrahydrofolate for (-P)-(+P) in Fig. 18 B, 
which is the difference between the amount of [3H]-5-methyltetrahydrofolate 
uptake in the absence and presence of 1 mM probenecid in Fig. 18 A, 
corresponds to the lower limit of the [3H]-5-methyltetrahydrofolate uptake 
through the probenecid-sensitive carrier into the cytoplasm when the folate 
receptors are working since there is no excess folic acid and the transport 
through the carrier is not 100 % inhibited in the presence of 1 mM probenecid 
(Fig. 3A and C). The amount of [3H]-5-methyltetrahydrofolate for (100xF)-
(100xF,+P) in Fig. 18 B, which is the difference between the amount of [3H]-5-
methyltetrahydrofolate uptake in the absence and presence of 1 mM probenecid 
(in the presence of 100-fold excess folic acid in both cases) in Fig. 18 A, 
corresponds to the lower limits of the [3H]-5-methyltetrahydrofolate uptake 
through the probenecid-sensitive carrier without the participation of the folate 
receptors. It is because 100-fold excess folic acid blocks the binding of [3H]-5-
rnethyltetrahydrofolate to folate receptors and could also reduce the transport of 
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[3H]-5-methyltetrahydrofolate to a certain extent by competetive inhibition. 
Comparing the the two values, i.e., the amount of [3H]-5-methyltetrahydrofolate 
for (-P)-( +P) and for (100xF)-(100xF, +P), it is suggested that the uptake of [3H]-5-
rnethyltetrahydrofolate through the probenecid-sensitive carrier is enhanced by 
the participation of folate receptors (Enhancement in Fig. 18 B). We believe that 
this could be strong evidence that the folate receptors and probenecid-sensitive 
carriers work in tandem to transport 5-methyltetrahydrofolate to the cytoplasm 
assuming that 1 mM proben~cid does not interfere with the acidification of the 
lumen of the endosomes (Fig. 2 A). However if probenecid interferes with 
acidification of the membrane vesicles by an as yet unknown mechanism and 
interferes with the release of 5-methyltetrahydrofolates from the receptors 
instead of blocking the carriers in the membrane vesicle, it could also inhibit the 
transport of 5-methyltetrahydrofolate transport into the cell cytoplasm (Figs. 17 C 
and D). If this is true, our data shown in Fig. 18 are also compatible with the 
independent model shown in Fig. 2 B. However, an effect of probenecid on the 
pH of endosomes has not been reported. 
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DISCUSSION 
Our results from the experiments with folic acid and probenecid inhibition 
suggest that KB cells have a probenecid-sensitive anion carrier as well as the 
folate receptor for intracellular 5-methyltetrahydrofolate uptake. The uptake of 
5-methyltetrahydrofolate by the probenecid-sensitive carrier was competitively 
inhibited by folic acid, probenecid and methotrexate. The carrier has a much 
smaller affinity for folic acid than for 5-methyltetrahydrofolate and methotrexate. 
These characteristics are similar to those of the reduced-folate carrier in L1210 
mouse leukemia cells ( 4). 
Our data show that probenecid can interfere with endocytosis of folate 
receptors at high concentrations (Fig. 9). We do not know exactly how high 
concentration of probenecid affects the endocytosis of folate receptors. It has 
been shown that probenecid has a very broad affinity for anion transport systems 
(19). Besides the reduced-folate carrier, probenecid inhibits the transport of 
sulfate (20), pthalate (69), lactate (69), chloride (70), urate (71), citrate (72), a-
ketoglutarate (72) and a leukotriene (73). It has also been shown that probenecid 
lowers the level of ATP in the cell and also changes membrane potentials (19) . If 
the endocytosis rate is coupled to the concentration of intracellular ATP, the rate 
of endocytosis might be reduced by reduction of ATP concentrations in the cell 
due to an as yet unknown action of probenecid. 
It is not clear whether probenecid can interfere with intracellular pH 
regulation. In order to determine the effect of probenecid on the pH of 
endosomes, we tried to measure the pH of the environment where folate 
receptors are endocytosed in KB cells using folate-conjugated BSA derivatives 
which were modified with a few molecules of a pH-sensitive fluorescent probe 
(DM-Nerf, molecular probe). However, the fluorescence of the conjugates taken 
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up by KB cells for 24-48 hours was undetectable and we could not measure the 
pH change due to probenecid (data not shown). In order to test whether 
probenecid actually interferes with the acidification process, folate-conjugated 
liposomes containing a pH-sensitive fluorescent probe such as 8-hydroxy-1,3,6-
pyrenetrisufonate (74) would be useful to monitor the change of pH due to 
probenecid. Recent studies have identified different systems which regulate 
intracellular pH (ref.75, Fig. 19). It has been shown that Na+ JH+ antiporter, 
Na+-dependent Cl- /HC03- exchanger, ATP-dependent proton pump are 
resposible for akalization of the cell cytoplasm whereas Na+-independent Cl-
/ HC03- and exchanger and Na+ /HC03- symporter are responsible for 
acidification. Recently, Madshus et al. (76) reported that probenecid and 
ethacrynic acid inhibited the intracellular uptake of 36Cl- ion by the Na+-
independent Cl-/HC03- exchanger in Vero cells. The intracellular alkalization 
induced by removal of extracellular chloride in the absence of Na+ ion was 
inhibited by ethacrynic acid. However, the intracellular pH change mediated by 
Na+-dependent Cl- /HC03- exchanger in cells given an acid load was not 
affected by the drugs. Considering the directionality of acidification, it is 
believed that the Na+-dependent Cl- /HC03- exchanger is responsible for 
acidification of endosomes. Therefore, probenecid is not likely to inhibit the 
acidification of endosomes. Puceat et al. (77) reported that in rat cardiac cells, 
probenecid, ethacrynic acid and 4,4'-diisothiocyanatostilbene-2,2'-disulphonic 
acid (DIDS) inhibited the intracellular acidification which was induced by 
extracellular ATP in the presence of Mg2+ ion. It has been proposed that the 
extracellular ATP activates Cl- I HC03- exchanger in the presence of Mg2+ ion 
(77). It is not known whether the folate receptor-mediated endocytosis is 
associated with the Cl-/HC03- exchanger. Furthermore, the assay media did not 
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contain any ATP molecules in our experiments. Therefore, it is unlikely that 
probenecid interferes with the acidification of the endosomes associated with the 
folate receptor-mediated endocytic pathway. Further studies are required to 
verify this. 
Assuming that probenecid did not interfere with the release of the 5-
methyltetrahydrofolate from the folate receptors due to the acidification of 
endosomes containing folate receptor-5-methyltetrahydrofolate complexes (see 
Figs. 17 Band 18), our data s_uggested that in KB cells there exists a mechanism 
by which the occupancy of folate receptors by 5-methyltetrahydrofolate enhances 
the uptake of 5-methyltetrahydrofolate through the probenecid-sensitive anion 
carrier at physiological concentrations. The folate receptor is known to recycle 
between the cell surface and an as yet undetermined intracellular location in KB 
cells (34, 55). It is attached to the membrane surface through a glycosyl-
phosphatidylinositollinker (37). Therefore, it might be energetically unfavorable 
for the folate receptor to move across the plasma membrane to deliver the 
vitamin to the cytoplasm while it recycles between the surface and inside of the 
cell. This implies that the folate receptor is internalized by endocytosis (34, 54 
Fig. 2). It might be also energetically unfavorable for folates with negatively 
charged carboxyl groups to diffuse into the cytoplasm across the membrane 
unless they are protonated (Fig 2 B). Antony et al. (78) reported that folates can 
diffuse into the cell cytoplasm when they are protonated in acidic compartments. 
However, it is not certain whether this is actually occurring in the cell at 
physiological concentrations of folates. In order to explain this apparent 
enhancment of the vitamin transport through the probenecid-sensitive carrier by 
folate receptors at physiological vitamin concentrations, it could be suggested 
that the 5-methyltetrahydrofolate molecules are transported to the cytoplasm 
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through the probenecid-sensitive carriers after the vitamin-folate receptor 
complexes are endocytosed in a vesicle which may or may not pinch off from the 
plasma membrane into the cell (cf Fig. 2 A) . If the endocytosed 5-
methyltetrahydrofolates are released from the receptors inside the small 
membrane vesicle, this would create a concentrated vitamin solution in a vesicle 
(cf Fig. 2 A). For example, if the folate receptors release only 25 molecules of 5-
methyltetrahydrofolate in a vesicle with the diameter of 100 nm , the final 
concentration of the vitamin in the vesicle would be 10 ~M, which is enough to 
drive the transport of the vitamin into the cytoplasm. This interpretation is 
analogous to the model of Rothberg et al. (56) in MA104 monkey kidney cells, 
where the 5-methyltetrahydrofolates are transported through probenecid-
sensitive transporters after they are endocytosed and concentrated in the 
caveolae (Fig. 2 A). In MA104 cells, about 750 receptors form a cluster on the 
plasma membrane and there are about 800 clusters per cell (56). 
There have been several reports about cell lines which have folate receptors 
and impaired reduced-folate carriers (79-81). Studies of membrane transport of 
folates or folate analogs in cell lines with folate receptors and impaired reduced-
folate carriers have often suggested that the two systems work independently 
(79, 80, 82). Dixon et al. (79) recently reported that methotrexate accumulation 
into human breast cancer cells (ZR-75-1) involved a system with characteristics of 
the reduced-folate carrier, that methotrexate resistant cells (MTRR ZR-75-1) 
which were isolated from the ZR-75-1 cells did not have a carrier for 
methotrexate transport, and that the two cell lines did not have folate receptors. 
The two cell lines which did not have folate receptors, could not grow in media 
containing less than 100 nM folic acid. When they expressed folate receptors in 
the two human breast cancer cell lines by gene transfection, the two cell lines 
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were able to grow in media containing only 1 nM folic acid. The accumulation 
of folic acid, folinic acid, and methotrexate was enhanced in the ZR-75-1 cells and 
MTRR ZR-75-1 cells by expressing folate receptors. The uptake of folates and 
methotrexate was similar in both cell lines expressing folate receptors. Therefore, 
they suggested that alterations in the reduced-folate carrier did not affect the 
folate receptor function much, thereby, the reduced-folate carrier and the folate 
receptor work independently (79). However, more folate receptors were found 
in the ZR-75-1 cells than in MTRR ZR-75-1 cells after transfection and accurate 
comparison of folate uptake in the two cell lines was not possible. If the 
reduced-folate carrier and the folate receptor work completely independently, it 
might be possible to isolate cell-lines without any reduced-folate carrier but with 
folate receptors. If the two systems work dependently as suggested by Rothberg 
et al. (56), it might not be possible to isolate a cell-line with only the folate 
receptors since in such a cell-line folates would be endocytosed by cells but 
would never reach the cytoplasm unless simple diffusion of folates across the 
plasma membrane occurs at a reasonable rate to support cell growth. The MTRR 
ZR-75-1 cells which were reported not to have any functional reduced-folate 
carrier nor folate receptors could grow in media containing 1 JlM folic acid. If 
one of the two systems were abolished completely, the cells could not survive. 
Therefore, this suggests that the MTRR ZR-75-1 cells had residual reduced-folate 
carrier activity. The CEM/MTX cell line, which was isolated from human CCRF-
CEM leukemia cells by culturing them at high concentrations of methotrexate for 
prolonged periods, was claimed to be "transport defective" (81). However in this 
cell-line there was still substantial reduced-folate carrier activity (17 % of parental 
cell line for 1 hour uptake of methotrexate uptake, ref. 81). L1210/R81 cells 
which have been shown to express the secondary low capacity transport system 
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by Henderson et al. (31) did not have the reduced-folate carrier nor the folate 
binding protein. The lack of the reduced-folate carrier was therefore, 
compensated for by the presence of this novel transport system. Therefore, the 
effect of absence of the reduced-folate carrier on the survival of this cell line 
could not be measured. Recently, Matsue et al. (83) reported that expression of 
folate receptors in PAM 212 cells, a mouse keratinocyte cell line, induced by gene 
transfection enabled the cells to grow in media containing 1 nM 5-
methyltetrahydrofolate, in which untransfected parental PAM 212 cells cannot 
proliferate. It should be interesting to see if this cell line has the reduced-folate 
carrier or not. If this cell line does not have any functional reduced-folate carrier, 
this would be strong evidence for the model in which folate receptors and the 
reduced-folate carriers work independently. 
We do not know whether the folate receptors are associated with caveolae 
or with other membrane organelles such as clathrin coated pits in KB cells. 
Leamon et al. (63) reported that folate-conjugated bovine serum albumin and 
horseraddish peroxidase were taken up by KB cells. The former was shown to 
be intact in the cell by polyacrylamide gel-electrophoresis and the latter also 
retained its catalytic activity. This indicates that in KB cells the endocytosed 
folate-conjugated macromolecules were not delivered to the lysosomal 
compartment where those molecules could be degraded by proteases. This fact 
favors the caveolae model (5). 
We do not know how the vitamin molecules could be released from the 
receptors in the vesicle if they are endocytosed in KB cells. Kamen et al. (54) 
reported that in MA104 cells the uptake of the 5-methyltetrahydrofolate was 
inhibited by monensin, the potassium-sodium ionophore (84, 85). They reasoned 
that monensin interferes with the establishment of low pH in the caveolae, 
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thereby inhibiting the dissociation of 5-methyltetrahydrofolate from the 
receptors, and further the transport of it into cytoplasm (54). A similar 
mechanism could apply to the KB cells. 
Our data (Fig. 3 B) suggest that the folate receptors might be down-
regulated in the presence of high concentrations of 5-methyltetrahydrofolate. 
This indicates that the rate of uptake of 5-methyltetrahydrofolate could be down-
regulated by reducing the number of vitamin-receptor complexes that are 
endocytosed. Further studies are required to understand how the sequential 
events of 5-methyltetrahydrofolate uptake are triggered and controlled in KB 
cells and other cells. 
We have not studied the efflux of [3H]-5-methyltetrahydrofolate in KB cells. 
In order to understand the relationship between the probenecid-sensitive carrier, 
folate receptor and yet unidentified efflux carriers in KB cells further studies 
should follow. 
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IMPLICATIONS AND FUTURE RESEARCH 
5-Methyltetrahydrofolate uptake mechanism We studied the roles of the 
folate receptor and an anion carrier with the characteristics of the reduced-folate 
carrier in KB cells. We were able to show that KB cells have an anion carrier for 
5-methyltetrahydrofolate uptake, which was not known previously. We were 
also able to provide evidence that probenecid, which was previously considered 
to inhibit only several anion carriers, inhibits the endocytosis via the folate 
receptors as well. We examii"~:ed two current models of 5-methyltetrahydrofolate 
uptake in cells in detail (Fig. 2). Assuming that probenecid did not interfere with 
the release of the 5-methyltetrahydrofolate from the folate receptors due to the 
acidification of endosomes containing folate receptor-5-methyltetrahydrofolate 
complexes, our data suggested that the 5-methyltetrahydrofolate molecules are 
transported to the cytoplasm through the probenecid-sensitive carriers after the 
vitamin-folate receptor complexes are endocytosed in a vesicle (see Figs. 17 Band 
18). However, if the assumption is not correct, currently available data from this 
research and from other studies are compatible with both of the models (see Fig. 
17 C and D). Future research should be focused on the effect of probenecid on 
cellular pH regulation in more detail. Also, other specific inhibitors for the 
reduced-folate carrier, such as the N-hydroxysuccinimide ester of methotrexate 
could be employed instead of probenecid to avoid some of these complications. 
The effect of this reagent on the various steps of the 5-methyltetrahydrofolate 
uptake should be investigated in combination with folic acid. In order to block 
folate receptors, antibodies against the folate receptors could be used to avoid the 
possible complications due to the effect of folic acid on the uptake of 5-
methyltetrahydrofolate. 
61 
Folate receptor-mediated endocytosis as a potential drug delivery route; 
an alternative to the clathrin-coated pit endocytic pathway Folate uptake 
pathways have been the subject of intensive studies for the past several decades 
since the discovery was made that methotrexate and other chemotherapeutic 
agents for leukemia utilize the reduced-folate carrier for cellular entry (3, 4, 5, 6). 
Development of the resistance of cancer cells to these antifolate chemotheraputic 
agents also prompted the search for alternative pathways and led to the 
discovery of several different transport systems for folate and antifolate 
compounds in mammalian cells (7, 11, 29, 31, 33, 34, 55). Strategies to design 
new antifolates depend on the mechanisms folate uptake. 
Recently, the folate-receptor endocytosis pathway has been investigated 
from a different point of view for an alternative drug delivery route into cells by 
Leamon et al. (63) . They showed that folate-conjugated BSA internalized by KB 
cells was intact using 50S/polyacrylamide gel electrophoresis. They also 
showed that the DL-5-methyltetrahydrofolate-conjugated horseraddish 
peroxidase retained its enzymatic activity after its uptake by KB cells. These 
results are consistent with the findings by Rothberg et al. (56) that folate 
endocytosis (potocytosis, ref. 5) occurs via membrane pits (caveola) which are 
different from clathrin-coated pits. Molecules that are endocytosed by the 
clathrin-coated pit endocytic pathway are eventually delivered to lysosomes 
where the endocytosed molecules are digested by digestive enzymes (86). The 
findings by Leamon et al. (63) suggests that folate receptor endocytosis is not 
related to the lysosomal cycle. They have recently shown that folate-conjugated 
plant toxin (momordin) is taken up by the KB and HeLa cells and inhibits protein 
synthesis inside the cell (87), suggesting that a folate-conjugated protein can be 
delivered to cell cytoplasm via folate receptor-mediated endocytic pathway. 
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Momordin is a single polypeptide plant toxin with a molecular weight of 31 kDa, 
which inactivates ribosomes, thereby inhibiting protein synthesis (88). In a time-
course uptake experiment, Leamon et al. (87) showed that after incubation for 5 
hours about 24 % of the cell-associated (cell-surface bound and internalized) 
folate-momordin conjugates were taken up and that the uptake increased 
steadily to 32 % in 50 hours. In contrast, protein synthesis was not affected for 
the first 5 hour incubation. Protein synthesis began to be affected after 5 hours 
and was fully inhibited after 50 hours. These data suggested that release of toxin 
conjugate into the cytoplasm does not occur immediately upon entry into the cell 
by endocytosis, but instead takes several hours before access to the ribosome is 
achieved. Leamon et al. (87) suggested that folate-conjugated momordin was 
endocytosed via the folate uptake pathway and translocated into cell cytoplasm 
by an as yet undefined mechanism. Momordin is a member of a family of 
ribosome inactivating proteins from plants (89, 90) . It exists in the seeds of 
Momordica charantia (bitter pear melon, ref. 88). It inactivates ribosomes in cell-
free systems, but has very little effect on intact cells (88). It has been shown that 
the toxin becomes very cytotoxic if it is conjugated through a disulfide bond to 
antibodies which are specific to target cells (91-93). Gelonin, a plant toxin similar 
to momordin also has similar properties (94, 95). It has been suggested that 
toxins conjugated to antibodies are endocytosed by target cells and the 
endocytosed immunotoxins are processed such that the toxins can translocate to 
the cell cytoplasm (96). This implies that the momordin or gelonin has an 
intrinsic ability to tranlocate into cell cytoplasm once it is endocytosed, although 
little is known about the translocation mechanism. It might be possible that 
folate-conjugated momordins are endocytosed by folate receptor-mediated 
endocytosis, processed inside the cell and delivered to the cell cytoplasm by a 
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similar mechanism. In other words, it might be possible that folates in the folate-
momordin conjugates serve merely as ligands to folate-receptors on the cell 
surface but folates might not be directly involved in the translocation of the 
folate-momordin conjugates into the cell cytoplasm after endocytosis. It is not 
clear whether proteins such as bovine serum albumin or horseraddish peroxidase 
can translocate into the cell cytoplasm by conjugation to folates (63). It might be 
possible that these proteins could not cross the membrane and remain in 
intracellular vesicles whereas momordin translocates to the cell cytoplasm using 
an as yet undefined cellular protein-translocation mechanism (87) . Therefore it 
remains to be determined whether the method of folate conjugation can be 
extended to other toxins such as diphtheria toxin fragment A (97-101) in order to 
deliver them to the cell cytoplasm using the folate-uptake pathway. 
Cellular entry and cytotoxicity of bacterial toxins Certain bacteria and 
plants produce proteins that are strongly cytotoxic to mammalian cells (97-101, 
reviews). Bacterial toxins, such as diphtheria toxin (DT) and Pseudomonas 
exotoxin A (PE), enter mammalian cells and kill them by inhibiting protein 
synthesis (Fig. 20). 
Diphtheria toxin (DT) is secreted as a single polypeptide from 
Corynebacterium diphtheriae that has been lysogenized by a bacteriophage 
carrying a DT gene (see Fig. 21, ref. 102). X-ray structure analysis shows that 
diphtheria toxin has three functional domains (103): a catalytic domain at the 
amino terminus, a receptor domain at the carboxyl terminus and a 
transmembrane domain which functions in the translocation of the catalytic 
domain to the cytoplasm of a target cell. Mild trypsinization and reduction of 
DT in vitro generates two fragments, fragment A (amino terminal, about 21 K) 
and fragment B (carboxyl teminal, about 37 K), as a result of cleavage at residue 
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190, 192 or 193 between the catalytic domain and transmembrane domain (104, 
105). A similiar proteolytic cleavage occurs in vivo before or soon after the toxin 
binds to a sensitive cell (106). The catalytic domain and transmembrane domain 
are covalently linked by a disulfide bond (see Fig. 21). The catalytic domain has 
a NAD+ binding site (103). The toxin is catalytically inactive until it is processed 
and the NAD+ binding pocket is exposed by the cleavage of the catalytic domain 
from the whole toxin (103). After the receptor domain recognizes its ligand on a 
target cell, the bound toxin is endocytosed via the clathrin-coated pit (receptor-
mediated endocytosis, see Fig. 20., ref. 97, 98). Upon entry into the lysosome, low 
pH in the lysosome induces a conformational change of the toxin and the 
hydrophobic transmembrane domain inserts into the membrane of the lysosome 
(107-109). In the lysosome the catalytic domain is released from the 
transmembrane domain after cleavage between the catalytic domain and the 
transmembrane domain by a trypsin-like cellular protease and after reduction of 
the disulfide bridge which links the two domains (104-106). It has been proposed 
that the catalytic domain partially unfolds for translocation into cytosol (110). 
The transmembrane domain permeabilized the cell membrane to sulfate and 
sucrose in addition to monovalent cations and therefore, the formation of a 
cation-channel in the cell membrane was implicated (111). It has been shown 
that the formation of a cation channel is important for the translocation of the 
catalytic domain across the plasma membrane and that the low pH requirement 
for the translocation of the catalytic domain (A fragment) is partly determined by 
the B fragment (transmembrane domain and the receptor domain) (112). 
However, it is not known in detail how the B fragment assists translocation of the 
catalytic domain to the cytosol. Inside the cytoplasm, the catalytic domain 
transfers the ADP-ribose moiety, derived from NAD+, to a modified histidine, 
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diphthamide of an elongation factor EF-2 (113). ADP-ribosylated EF-2 can no 
longer support protein synthesis and this leads to cell death (114). A single DT 
molecule can kill a cell(115). According to Chaudhary et al. (116), theN-terminal 
sequence of diphtheria toxin, Gly-Ala-Asp-Asp-Val-Val-Asp (GADDVVD, theN-
terminus of catalytic domain) is important for the cytotoxicity of the toxin. When 
the N-terminal sequence was deleted by mutagenesis, the cytotoxicity of the 
whole toxin molecule was reduced without affecting either cell-binding or ADP 
ribosylation activity (116). 
A mature Pseudomonas exotoxin A (PE) is also a single polypeptide which 
consists of three functional domains (Fig. 21 b, refs 97, 98). In Pseudomonas 
exotoxin A, the order of the fuctional domains is opposite to that of DT (97, 98, 
117, 118). The receptor domain is located at the N -terminal region. The catalytic 
domain with ADP ribosylation activity is at the carboxyl terminal region. The 
transmembrane domain is in the middle. A small segment of polypeptide which 
links the transmembrane domain and the catalytic domain is also a part of the 
receptor binding domain (118). PE enters a target cell by receptor-mediated 
endocytosis similar to DT (119, see Fig. 20). It is believed that unlike DT, the PE 
catalytic domain is translocated into the cytoplasm after the toxin is delivered to 
trans-Golgi network via coated pits (120) . When target cells were treated with 
Brefeldin A which disrupts the Golgi apparatus of the cell (121), the cytotoxicity 
of PE was abolished whereas the cytotoxicity of DT was not affected (120) . It has 
been shown that the carboxyl terminal sequence Arg-Glu-Asp-Leu-Lys (REDLK) 
of PE is required for its cytotoxicity (122). It has been proposed by Chaudhary et 
al. (122) that the REDLK sequence is involved in the retention of the catalytic 
domain in the intracellular compartment. When the REDLK sequence was 
replaced with KDEL, an endoplasmic reticulum retention signal sequence of 
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cellular proteins, the cytotoxicity of PE was enhanced compared to the wild-type 
PE with the REDLK carboxyl terminal sequence (123). 
Differential cytotoxicity of liposome-encapsulated gelonin and diphtheria 
toxin fragment A It has been shown that liposomes can be used to deliver some 
toxin molecules into the cytoplasm. Mcintosh et al. (125) reported that gelonin 
encapsulated in liposomes could be delivered to the cytoplasm of cells to inhibit 
protein synthesis. They showed that gelonin showed cytotoxicity to TLX5 cells (a 
CBA/Ca mouse T lymphoma), XC cells (Rous sarcoma virus transformed rat 
fibroblasts) and phytohaemagglutinin-stimulated CBA mouse lymphocytes, 
when gelonin was encapsulated in phosphatidylserine liposomes, 
phospha tid ylcholine I cholesterol (1: 1 molar ratio) li posomes, or 
phosphatidylcholine/ cholesterol/ ganglisodes (5 : 5: 1 molar ratio) liposomes. 
Gelonin and lipid alone or mixed showed no toxicity. However, diphtheria toxin 
fragment A encapsulated in phophatidylserine liposomes had no effect on the 
level of protein synthesis in TLX5 cells or Daudi cells, a human lymphoblastoid 
B-cellline known to be sensitive to whole diphtheria toxin. Both toxins showed 
enzymatic activity after encapsulation or radioiodination. The encapsulated 
toxins were released from the the vesicles by incubation with 0.05% Triton-X 100 
for 30 min room temperature. Released gelonin retained 90 %of the control and 
diphtheria toxin fragment A retained 100 % of control (untreated toxin). Lysed 
liposomes containing buffer had no inhibitory effect on the levels of protein 
synthesis. Uchida et al. (126) also reported that liposome encapsulated 
diphtheria toxin fragment A was not cytotoxic. However, when the same toxin 
was encapsulated in reconstituted Sendai virus vesicles which can fuse with 
target cell plasma membranes, it exerted cytotoxicity to the cells. If the delivery 
of liposome contents were a result of fusion with the plasma membrane, both 
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gelonin and the A chain of diphtheria toxin would be injected into the cytoplasm 
and would exert their effects equally. Therefore, the experimental results of 
Mcintosh et al. (125) and Uchida et al. (126) suggest that the delivery of liposome 
contents were not the result of membrane fusion. If the delivery of liposome 
contents involved the endocytosis of liposomes by the cell, lysis of the liposomes 
in the endosomes and processing of the toxins in the endosomes for translocation 
to cytoplasm, the differential effects of liposome encapsulated gelonin and 
diphtheria toxin fragment A could be explained (125). It might be possible that 
gelonin was processed in the cell and delivered to the cell cytoplasm whereas 
diphtheria toxin fragment A was not (125). As discussed in the above section, 
translocation of diphtheria toxin fragment A requires the cooperation of 
fragment B. Therefore, it could be explained why the diphtheria toxin fragment 
A encapsulated in liposomes was not cytotoxic unlike gelonin. 
A test for the possible use of folate conjugation for drug delivery of 
macromolecules As stated above, it remains to be determined whether the 
method of folate conjugation (87) can be extended to any therapeutic molecules 
such as oligonucleotides in order to deliver them to the cell cytoplasm using the 
folate-uptake pathway. Since it has been shown that diphtheria toxin fragment A 
can not translocate to the cell cytoplasm without the cooperation of fragment B, it 
would be useful to test whether folate conjugation could overcome this barrier. 
If it turns out that folate conjugated-diphtheria toxin fragment A shows 
cytotoxicity, this would suggest that there exists a cellular mechanism by which 
folate-conjugated macromolecules reach the cell cytoplasm. If not, this would 
suggest that the folate conjugation method could not be generalized for the 
delivery of macromolecules to the cell cytoplasm. However, even in the case in 
which folate conjugation can not be generalized for the delivery of 
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macromolecules, the folate receptor-mediated endocytosis pathway might be still 
useful as a drug delivery pathway as an alternative to clathrin-coated pit 
endocytic pathway if folate-conjugated liposomes are used. Folate-conjugated 
liposomes might be able to fuse with the endosomes after folate receptor-
mediated endocytosis and the liposome contents will be delivered to the cell 
cytoplasm (Fig. 22). This would be more advantageous than endocytosis via 
clathrin-coated pits for the delivery of drugs since the delivered molecules would 
not be damaged by the lysosomal enzymes. Additionally, folate receptors are 
expressed in some normal or cancer cells. Weitman et al. (127) reported limited 
expression of the folate receptor in a large number of normal human tissues such 
as choroid plexus, lung, thyroid, and kidney . . The liver, intestines, muscle, 
cerebellum, cerebrum, and spinal cord did not have a detectable amount of folate 
receptor (127). They also reported that some brain tumors such as anaplastic 
ependymoma from cerebellum, subependymal giant cell astrocytoma from 
lateral ventricle, high-grade sarcoma from occipital lobe and juvenile pilocytic 
astrocytoma from cerebellum overexpress folate receptors (127). Folate receptors 
have also been found in some ovarian cancer cells (128) . Therefore, the folate 
receptor pathway may be a useful target for liposome-mediated drug delivery as 
well as for selective immunotherapy or chemotherapy (87, 127). 
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FOOTNOTES 
1 The abbreviations used are: 5-Mei-Ltfolate, 5-methyltetrahydrofolate; 
[3H]-5-MeH4folate, (6S)-5-methyltetrahydro[3', 5', 7, 9-3H]pteroylglutamate; 
[3H]-folic acid, [3', 5', 7, 9-3H]pteroylglutamate; probenecid, p-[dipropyl-
sulfamoyl]benzoic acid; MEM, minimum essential medium; fdDMEM, folate-
deficient Dulbecco's modified Eagle's medium; FCS, fetal calf serum; HEPES, 4-
(2-hydroxyethyl)-1-piperazineethanesulfonate; DPBS, Dulbecco's phosphate 
buffered saline; EDTA, e thylenediaminetetraacetate. 
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Table. 1. Transport systems for folate and antifolate uptake 
Abbreviations: NHS-MTX, N-hydroxysuccinimide ester of methotrexate; 
pCMBS, p-chloromercuribenzene sulfonate; DIDS, 4-4'-diisothiocyano-2,2'-
disulfonic acid stilbene; SITS, 4-acetamido-4'-isothiocyano stilbene-2,2'-
disulfonic acid; NEM, N-ethylmaleimide; BSP, bromosulfophthalein, L1210, 
mouse leukemia cells; L1210/R81, subcellline of L1210 cells; ZR-75-1, human 
breast cancer cells; MA104, monkey kidney cells; CCRF-CEM, human leukemic 
cells 
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Table 2. Membrane carriers involved in methotrexate efflux in L1210 cells 
Abbreviations: see Table 1. 
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Fig. 1. Structures of pteroic acid, folate derivatives, probenecid and a 
glycosylphosphatidylinositollinker 
(A) pteroic acid (B) folic acid (C) 7,8-dihydrofolic acid (D) (65)-5,6,7,8,-
tetrahydrofolic acid (L-isorner) (E) (65)-5-rnethyltetrahydrofolic acid (F) 
methotrexate (G) pteroylpolyglutarnate (H) probenecid (I) glycosyl 
phosphatidylinositol (GPI) linker 
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Fig.l 
A. Pteroic acid 
B. Pteroylglutamic acid (folic acid) 
1 o s_· 6' COOH 
0 9 NH~ I . H~~r,%'cH; -y.-coNH-CH-Cflz-CH,-cooH 
H2N XN~NJ7 . 
C. Dihydrofolic acid (7,8-) 
0 
10 s_· 6' COOH 
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H 2N N SaN H 
D. (68)-5,6, 7 ,8-tetrahydrofolic acid (L-isomer) 
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E. (68)-5-methyltetrahydrofolic acid (L-isomer) 
5' 6' COOH 
to~ I 
0 CH3 /NH-u-CONH-CH-CHrCHrCOOH 
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H. Probenecid; p-(dipropylsulphamoyl)-benzoic acid 
~ 9-o 

















box; conserved structure 








This was adapted from Ferguson, M. A. J ., reference 39. 
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Fig. 2. Models for folate uptake 
(A) A model for folate uptake in which folate receptors and anion carriers work 
in tandem to transport folates into a cell. Folates bind to the folate receptors 
bound to the cell membrane (b), and a proton gradient is generated (c) that 
causes the folate to dissociate from the receptor (d). Folates move across the 
membrane by an anion carrier due to the high folate concentration generated in 
the caveola (e). The caveola reopens to initiate another round of folate uptake (f) 
and the transported folates are polyglutamated in the cytoplasm to retain the 
vitamins within the cell (g). This figure was adapted from R. G. W. Anderson et 
al. (5). 
(B) An alternative model for folate uptake in which folate receptors and carriers 
work independently to transport folates into a cell. Folates bind to membrane-
bound receptors (a) and the vitamin-receptor complexes are endocytosed (b). A 
proton gradient is generated (c) and folates dissociate from the receptors (d). 
Folates move across the membrane by simple diffusion (ref. 74) or by an 
unknown mechanism (e) and the vesicle which could be the caveola or not 
recycles to the cell surface (f). Independently, anion carriers transport folates into 
cytoplasm (i and ii). The folates are polyglutamated in the cytoplasm (g). 
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Fig. 2. Models for folate uptake 
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Fig. 3. Binding of S-MeH4folate to KB cells 
(A) Concentration dependent binding of S-MeH4folate to folate receptors KB 
cells were incubated in the presence of [3H]-S-MeH4folate at the indicated 
concentrarions for 4 hours at 0 oc in duplicate. Acid-resistant (AR) and acid-
dissociable (AD) fractions were measured as described in MATERIALS AND 
METHODS. 
(B) Scatchard plot 
KB cells were incubated in the presence of [3H]-S-MeH4folate at the indicated 
concentrations for 4 hours at 0 oc in duplicate. Acid-dissociable (AD) fractions, 
concentrations of free S-MeH4folate in the incubation media and the mass of the 
cells per each flask were measured as described in the MATERIALS AND 
METHODS section. The parameter Vis defined as the moles of 5-MeB4folate 
bound per mole of a cell, which was calculated using acid-dissociable fractions 
and the amount of cells. The mass of 5.36xlo-7 mg per cell, which was 
measured as described in the MATERIALS AND METHODS section, was used to 
calculate the molar concentration of cells in this plot. [L) in the unit of nM is the 
free concentration of the S-MeB4folate in the incubation media. The intercept on 
the V-axis is the number of binding sites per cell (approximately 40xl06 
sites/ cell). The absolute value of the slope of a line connecting the intercepts of 
the curve with the V /[L]- and [L]- axis corresponds to the association constant of 
S-MeB4folate for the folate receptor. 
(C) and (D) 1/[L) vs. [m)/[AD) plot 
The equilibrium (association) constant between free 5-MeB4folate, free receptor 
and receptor-vitamin complex can be expressed in terms of acid-dissociable 
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fraction ([AD]), free vitamin concentration ([L]) and the concentration of 
cells([m]) as follows; 
R + L H RL·· · ···················· · ·· · ·· · (i) 
[RL] [AD] .. 
Ka = [R ][L] = (k[m]- [AD ])[Lj" .. (u) 
_l = kKa [m] - K .... · · · · · · · ·······(iii) 
[L] [AD] a 
where R, L, RL, Ka represent folate receptor, 5-MeH4folate, folate receptor-
vitamin complex and the association constant for the equlibrium reaction. Now 
[RL]=[AD] and [R]=[R1total-[RL]. If we define a constant k such that 
[R1total=k[m], we can express the association constant in terms of [AD], [L], [m] 
and k (equation (ii)). Rearranging the equation (ii) yields equation (iii). The 
intercept of the curve on [m]/[AD] axis corresponds to 1/k and that of on the 
1/ [L] axis corresponds to -Ka. Plot (D) shows the expanded region around the 
origin of the graph (C). Calculated k and Ka were 0.135 pmolfl..tg cell and 0.05 
nM-1. 
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Fig. 3 (D) Extrapolation of fig. 3 C 
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Fig. 4. Effect of probenecid on the uptake of [3H]-S-MeH4folate 
KB cells were incubated for 30 min at 37 °C in 0.5 ml fdDMEM containing 
varying concentrations of probenecid in duplicate. [3H]-5-methyl-
tetrahydrofolate ([3H]-S-MeH4folate) with (A) or without (B and C) 100-fold 
excess nonradioactive DL-5-Me~folate (100x mfol.) was added to the cells to a 
final concentration of 20 nM in a final 1 ml volume and cells were further 
incubated for 4 hours at 37 °C in the presence of probenecid at the final 
concentrations as indicated. Acid-resistant (ar, filled circle) and acid-
dissociable(ad, open circle) fractions of [3H]-S-MeH4folate were measured as 
described in MATERIALS and METHODS. Acid-resistant (AR) fractions 
represent the amounts of the [3H]-5-MeH4folate internalized by cells and acid-
dissociable (AD) fractions represent the amount of the vitamin bound to the cell 
surface. 
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Fig. 4 (A) Effect of probenecid on the uptake of [3H]-5-methyltetrahydrofolate 
in the presence of 100 fold excess DL-5-methyltetrahydrofolate 
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Fig. 4 (B) Effect of probenecid on the binding of [3H]-5-methyltetrahydrofolate 
to KB cells 
70 
~ 
I -- - I Cl) -..... 
Cl) ,.Q 60 = 0 ~ ·-...... 50-u ·-£ ~ £ I~ ad-20 nM I ~ ..;:: e - 40 ..8 Q) 0.. -..0 --.:t ~ = ·- Q) 30-Q) u u :E 0 01) Cl) g 20 I Cl) ·-V') "0 I I 0 ,..._, 
= "0 8 . 10 ·-('<':) u 0.. .......... ~ '-' 
0 
0 .0 2 .5 5.0 7 .5 10.0 
Probenecid (mM) 
96 
Fig. 4 (C) Effect of probenecid on the uptake of [3H]-5-methyltetrahydrofolate 
in the absence of 100 fold excess DL-5-methyltetrahydrofolate 
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Fig. 5. Effect of temperature and probenecid on the uptake of S-MeH4folate 
KB cells were incubated in the presence or absence of 10 mM probenecid in 0.5 
ml fdDMEM for 30 min at 37 °C. At the end of the incubation appropriate 
volumes of 20 IJ.M DL-5-MeH4folate solution containing 200 nM [3H]-5-
MeH4folate were added to the cells to a final volume of 1 ml at the indicated 
concentrations and temperatures. Cells were further incubated at the indicated 
temperatures for 4 hours. Total amounts of 5-MeH4folate associated per mg cell 
protein were calculated assuming that only the L-isomer can bind and translocate 
into cell. Only the concentration of L-isomer is shown in the plot. 
A. Acid-resistant fractions; open circle - at 37 °C without probenecid; filled 
square- at 37 °C with 5 mM probenecid; filled circle- at 0 °C without probenecid; 
open square- at 0 °C with 5 mM probenecid. 
B. Acid-dissociable fractions; The same legends were used as in (A). 
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Fig. 5 (A) Effect of temperature and probenecid on the uptake of 5-Mef4£olate 
by KB cells 
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Fig. 5 (B) Effect of temperature and probenecid on the binding of S-
.MeH4folate to KB cells 
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Fig. 6. Effects of folic acid and probenecid on the uptake of physiological 
concentrations of [3H]-S-MeH4folate 
KB cells were incubated in 0.5 ml fdDMEM containing either 0 or 10 mM 
probenecid for 30 min at 37 oc. At the end of the incubation, 200 nM [3H]-5-
MeJ-4folate solution with or without 100-fold excess folic acid was added to the 
cells to the indicated concentrations in a final volume of 1 ml. Cells were further 
incubated for 4 hours at 37 °C. Acid-dissociable and acid-resistant fractions were 
determined as described in MATERIALS and METHODS. Acid-dissociable and 
acid-resistant fractions are shown in A. and B., respectively using the following 
symbols; filled circle - without probenecid and folic acid; open circle - with 5 
mM probenecid; filled square- with 100x folic acid; open square- with SmM 
probenecid and 100x folic acid. Curves 1, 2, and 4 represent the mean values of 
two separate experiments and curve 3 represents the result of one experiment. 
Each experiment was performed using duplicate samples. 
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Fig. 6 (A) Effects of folic acid and probenecid on the binding of physiological 
concentrations of [3H]-s-MeH4folate to KB cells 
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Fig. 6 (B) Effects of folic acid and probenecid on the uptake of physiological 
concentrations of [3H]-s-MeH4folate by KB cells 
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Fig. 7 Endocytosis of folate-BSA conjugates by folate receptors 
(A) Uptake of [1251]-BSA and [l25I]-DL-5-MeH4folate-conjugated BSA ([1251]-
mfBSA) KB cells were preincubated in 0.6 ml fdDMEM for 30 min. BSA in 
fdDMEM (0.3 ml, 16.7 mg/ml BSA) was added to cells prior to the addition of 
[125J]-BSA or [125I]-5-MeH4folate-BSA (average 10 (± 1) DL-5-MeR4folates per 
BSA) in order to reduce the nonspecific binding of the modified BSA 
moleculecules to cells and culture flasks. [1251]-BSA or [1251]-5-Mei-Ltfolate-BSA 
in 50 mM Tris-HCl (pH7.5) were added to cells at various concentrations. The 
final volume of the media was adjusted to 1 ml with 50 mM Tris-HCl (pH 7.5). 
Cells were further incubated for 4 hours at 37 °C. Acid-dissociable fractions of 
[125!]-BSA(open square) and [1251]-mfBSA(filled square) and acid-resistant 
fractions of [125!]-BSA(open circle) and [1251]-mfBSA(filled circle) were 
determined as described in the MATERIALS AND METHODS section. The 
reported values are the averages of duplicate samples. 
(B) Effect of free DL-S-MeH4folate on the uptake of [1251]-mfBSA KB cells 
were incubated with 12 !J.g/ml [1251]-5-MeH4folate-BSA in the presence of 
varying concentrations of DL-5-MeH4folate in 1 ml media for 4-hours at 37 oc. 
Free BSA (5 mg/ml) was present in the media. Acid-dissociable (filled square) 
and acid-resistant (filled circle) fractions were measured as described in the 
MATERIAL AND METHODS section. The reported values are the averages of 
duplicate samples. 
(C) Effect of folate-BSA conjugate on the uptake of [3H]-folic add by KB cells 
KB cells were pre-incubated with folate-BSA conjugate (5.2 ±0.3 folate per BSA) 
in 0.5 ml fdDMEM at 0 °C for 15 min. [3H]-folic acid in a volume of 0.5 ml 
fdDMEM was added to the cells to a final concentration of 50 nM and cells were 
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further incubated for 30 min on ice. Flasks containing the cells were moved to a 
water bath at 37 oc and warmed for 10 min and transferred to an incubator at 37 
°C and incubated for another 30 min. After the incubation, media was removed . 
The cells were rinsed three times with 1 ml DPBS. Cells were washed twice with 
1 ml acid-saline solution (0.15 N NaCl, pH 3) for 30 seconds each time. Cells 
were rinsed with 1 ml DPBS. Cells were dissolved in 1 ml of 1 % SDS, 0.1 N 
NaOH solution. Flask was rinsed twice with 1 ml DPBS solution. Solubilized 
cells in total 3 ml volumes were used to determine the acid-resistant fractions as 
described in the MATERIALS AND METHODS section. Final concentrations of 
fol-BSA after addition of [3H]-folic acid are shown in the graph. The reported 
values are averages of duplicate samples. 
(D) Effect of probenecid, BSA and folate-conjugated BSA on the uptake of 
[3H]-S-MeH4folate by KB cells KB cells were incubated for 30 min at 37 °C in 
fdDMEM containing 90 nM [3H]-5-MefL!folate in the presence or absence of 1 
mM probenecid (P), BSA (BSA, 0.75 mg protein/ml), or folate-conjugated BSA 
(fol-BSA, 0.75 mg protein/ml). Acid-resistant fractions were determined as 
described in MATERIALS AND METHODS. Averages of five different 
experiments are reported (error bars, 95% confidence limit). 
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Fig. 7 (A) Uptake of [1251]-BSA and [125f]-DL-5-MeH4folate-conjugated BSA 
([1251]-mfBSA) 
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Fig. 7 (D) Effect of probenecid, BSA and folate-conjugated BSA on the uptake 
of [3H]-S-MeH4folate by KB cells 
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Fig. 8 (A) Effect of probenecid on the uptake of [125J]-5-MeH4folate-BSA by 
KB cells 
KB cells were preincubated in 0.5 ml fdDMEM containing 10 mM probenecid for 
30 min at 37 °C. BSA solution (0.3 ml, 16.7 mg/ml in fdDMEM) and 0.05 ml 50 
mM Tris·HCl were added to cells prior to the addition of [1251]-5-MerLtfolate-
BSA (5-MeH4folate/BSA ratio = 10 ± 1 for this preparation) to a final 
concentration of 12 !J.g/ml. Cells were further incubated for 4 hours at 37 oc. 
At the end of the incubation cells were chilled on ice and acid-dissociable 
fractions in the presence (filled circle) and absence (open circle) of probenecid 
and acid-resistant fractions in the presence (filled square) and absence (open 
square) of probenecid were determined from the samples prepared in dulicate as 
described in MATERIALS AND METHODS. 
Fig. 8 (B) Effect of varying concentrations of probenecid on the uptake of 
[125J]-5-MeH4folate-BSA conjugate by KB cells 
KB cells were incubated for 30 minutes at 37 °C in 0.5 ml fdDMEM containing 
probenecid at the indicated concentrations. After this, 0.1 ml fdDMEM, 0.3 ml 
BSA solution in fdDMEM (16.7 mg/ml) and 0.05 ml 50 mM Tris-HCl (pH 7.5) 
were added to the cells. Finally, [1251]-5-MerLtfolate-BSA (5-MeH4folate/BSA 
ratio = 10 ± 1 for this preparation) was added to the cells to a final concentration 
of 12 !J.g/ml in 1 ml total volume and further incubated for 4 hours at 37 oc. 
After addition of radioiodinated protein, the concentrations of probenecid were 
reduced to a half of the initial values. Acid-dissociable (filled circle) and acid-
resistant (open square) fractions were determined from the samples prepared in 
duplicate as described in MATERIALS AND METHODS. 
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Fig. 8 (A) Effect of probenecid on the uptake of [125I]-5-MeH4folate-BSA by 
KB cells 
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Fig. 8 (B) Effect of varying concentrations of probenecid on the uptake of 
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Fig. 9 Time-dependent uptake of 5 1-!g/ml S-MeH4folate-BSA conjugate and 
BSA by KB cells at 37 oc 
(A) KB cells were incubated with 5 11-g/ml radioiodinated 5-MeB4folate-BSA (5-
MeH4folate/BSA ratio = 11.7 for this preparation) in the presence of excess 5 
mg/ml BSA. Some experiments were performed in the presence of 5 mM 
probenecid or 10 11M folic acid. As a control, KB cells were incubated with 
radioiodinated BSA (5 11-g/ml) in the presence of 5 mg/ml BSA. Incubation 
periods were 10, 20, 25,30, 45, 60, 120, 180, and 240 minutes . Acid-resistant 
fractions of radioiodinated fractions were determined as described in 
MATERIALS AND METHODS. The experimental values are the averages of 
three different samples. (B) Fig. 9 B represents the expanded region of 0-60 min 
period in Fig 9 A. 
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Fig. 9 (A) Time-dependent uptake of 5 J.lg/ml s-MeH4folate-BSA conjugate 
and BSA by KB cells at 37 °C 
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Fig. 9 (B) Expanded region of 0-60 min period in Fig 9 (A) 
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Fig. 10. Effect of short-term incubation of KB cells in varying concentrations 
of probenecid on the uptake of S-MeH4folate-BSA conjugate by KB cells 
KB cells were incubated in the presence of 5!-Lg/ml radioiodinated 5-Mei-Ltfolate-
BSA conjugate (folate/BSA ratio= 11.7) for 30 min at 37 °C. Acid-resistant (AR) 
and acid-dissociable (AD) fractions were measured as described in MATERIALS 
AND METHODS. The experimental values are the averages of three different 
samples. 
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Fig. 10 Effect of short-term incubation of KB cells in varying concentrations of 
probenecid on the uptake of 5-MeH4fo1ate-BSA conjugate by KB cells 
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Fig. 11. Effect of probenecid on the time-dependent binding of S-MeH4folate 
to folate receptors 
KB cells were chilled on ice. [3H]-S-MeH4folate was added to cells to a final 
concentration of 20 nM in the presence or absence of 1 mM probenecid. Cells 
were incubated at 0 oc for 5, 10, 15, 30, 60, 120, 180 and 240 minutes. Acid-
dissociable fractions in the presence (AD-1mM P) or absence (AD-OmM P) of 
probenecid and acid-resistant fractions in the presence (AR-1mM P) or absence 
(AR-OmM P) of probenecid were determined as described in MATERIALS AND 
METHODS. Reported values are from single experiments for each time point. 
The amount of the cells per well of flask used in each experiment varied between 
0.26 and 0.41 mg/ml and the concentration of 10 nM 5-Methyltetrahydrofolate is 
not enough to saturate the folate receptors. 
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Fig. 11 Effect of probenecid on the time-dependent binding of s-MeH4folate 
to folate receptors 
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Fig. 12. Time-dependent uptake of S-MeH4folate in the presence of 0.5 mM 
folic acid 
KB cells were incubated with 50 nM [3H]-S-MeH4folate in the presence of 5 ~M 
DL-S-MeH4folate for 1, 3, 5, 6, 10, 15, 20, 25, 30 and 60 minutes at 37 °C. The 
amount of L-S-MeH4folate was measured as described in MATERIALS AND 
METHODS. The initial concentration of L-isomer of 5-Me~folate was 2.55 ~M. 
The experimental values were obtained from a single experiment for each time 
point. 
120 







~ .... ,..-.. liJ 
0.. c liJ 
~ ·-
~ ~ 6 - e liJ ~ - 0.. t.8 - liJ -.::t 
::I: ~ u 4 1!1 ~ 
~ 
OJ) 
g liJ Ia L-isomer 2.55 mcM I I V") 
I 0 ,..-.. 
E 2 CZl 
\0 0.. a --
0 
0 10 20 30 40 50 60 
time (min) 
121 
Fig. 13. Initial rates of S-MeH4folate uptake at varying concentrations of S-
MeH4folate 
A stock solution containing 0.5 11M [3H]-S-MeH4folate (L-isomer), 20 11M DL-S-
MeH4folate, and 1 mM folic acid was prepared and this stock solution was 
diluted (to final concentrations of 2, 4, 6, 8, 10 IJ.M of DL-5-MeB4folate). To KB 
cells 1 ml of the diluted solutions were added and incubated for the indicated 
times at 37 °C in a water bath. Acid-resistant fractions were determined as 
described in MATERIALS AND METHODS. Only the amount of L-form of the 
S-MeH4folate was reported at the indicated concentrations (L-isomer) from a 
single experiment. 
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Fig. 13. Initial rates of s-MeH4folate uptake at varying concentrations of S-
MeH4folate 
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Fig. 14. Effect of folic acid on the uptake of S-MeH4folate at a fixed 
concentration ratio. 
Stock solutions containing 0.5 !J.M [3H]-S-MeH4folate (L-isomer), 20 !J.M DL-S-
MeH4folate with or without 1 mM folic acid were prepared and these stock 
solutions were diluted to appropriate concentrations. To KB cells 1 ml of the 
diluted solutions were added and incubated for 3 minutes at 37 °C in a water 
bath. Acid-resistant fractions were determined as described in MATERIALS 
AND METHODS. Only the amounts of L-form of the 5-MeB4folate were 
reported at the indicated concentrations (L-isomer) from a single experiment. (A) 
Uptake of S-MeB4folate in the absence (Oxfolic acid) and presence (SOxfolic acid) 
(B) Lineweaver-Burk plot of Fig. 14 A 
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Fig. 15. Competitive inhibition of S-MeH4folate uptake by probenecid, folic 
acid and methotrexate. 
KB cells were incubated for 3 minutes at varying concentrations of D,L-5-
MeH4folate in the presence of trace amount of [3H]-5-MeH4folate at 37 oc. 
Appropriate volumes of solution containing 0.5 J...LM [3H]-5-MeH4folate (L-
isomer) and 20 J...LM DL-5-Mefittfolate were used to give the final concentration of 
total L-5-MeH4folate at the indicated concentrations in 1 ml. Similar 
experiments were also performed in the presence of 1 mM probenecid, 500 J...LM 
folic acid or 30 J...LM methotrexate. Acid-resistant fractions were determined as 
described in MATERIALS AND METHODS. The uptake of 5-Mefittfolate in the 
presence of 1 mM probenecid (A), 500 J...LM folic acid (B), or 30 J...LM methotrexate 
(C) is compared with control experiment without any inhibitor. Fig. 15 D, E and 
F show the Lineweaver-Burk plots of A, Band C, respectively. 
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Fig. 15 (A) Uptake of 5-methyltetrahydrofolate by KB cells in the presence or 
absence of 1 mM prpbenecid 
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Fig. 15 (B) Uptake of 5-methyltetrahydrofolate by KB cells in the presence or 
absence of 500 J...LM folic acid 
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Fig. 15 (C) Uptake of 5-methyltetrahydrofolate by KB cells in the presence or 
absence of 30 ~M methotrexate 
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Fig. 15 (E) Lineweaver-Burk plot of Fig. 15 (B) 
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Fig. 16 The rate of uptake of [3H]-folic acid by KB cells 
KB cells were chilled on ice for 30 minutes. Ice-cold [3H]-folic acid (1 ml of 100 
nM in fdDMEM) was added to the cells and further incubated on ice for 4-6 
hours to saturate the folate receptors. After incubation on ice, the media was 
removed and unbound folic acid was washed off by rinsing the cells three times 
with 1 ml DPBS briefly. After this, the flask was placed in the water bath 
warmed to 37 oc. At the same time, 1 ml fdDMEM (at 37 °C) was added to the 
cells and the media was shaken gently. The culture flasks containing cells were 
placed in a water bath at 37 °C for 1-15 min incubations. For prolonged 
incubations, cells were initially warmed up for 2 min in the water bath and 
moved into a cell culturre incubator at 37 °C. The amount of radioactive folic 
acid in the the media, acid-dissociable fractions and acid-resistant fractions were 
determined as described in MATERIALS AND METHODS. (A) % Change of 
acid-resistant and acid-dissociable fractions as a function of time. (B) % Change 
of [3H]-folic acid in the medias as a function of time. (C) Acid-resistant fractions 
as a function of time. (D) Rate of endocytosis for the initial 15 min. This is the 
expanded region of graph (A) for 1-15 min period. 
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Fig. 16 (A) % Change of acid-resistant and acid-dissociable fractions as a 
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Fig. 16 (D) Rate of endocytosis for the initiallS min 
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Fig. 17. Experimental scheme to define the interrelationship between the 
folate receptor and a probenecid-sensitive anion carrier in the transport of 
[3H]-S-MeH4folate 
Figures (a), (b), (c), and (d) in Figs. 17 (A), (B), (C), and (D) show the schematic 
representation of [3H]-S-MeH4folate uptake via folate receptor-dependent and 
folate receptor-independent pathway under various conditions: (a), without folic 
acid and probenecid; (b), with 1 mM probenecid; (c), with 100 fold excess folic 
acid; (d), with 100 fold folic acid and 1 mM probenecid. The arrows associated 
with a circle (the caveola), represent [3H]-S-MeH4folate uptake via folate 
receptors and the probenecid-sensitive carrier. The arrows associated with 
isolated carrier represent the [3H]-5-MeH4folate uptake without the participation 
of the folate receptor, i.e., uptake through the probenecid-sensitive carrier when 
the carrier is exposed to culture media. The lenth of the arrows represent the 
amount of [3H]-5-MeH4folate uptake in an arbitrary unit. E represents the 
amount of [3H]-5-MeH4folate in the endocytic vesicle when the vesicle is closed. 
R represents the amount of [3H]-5-MeH4folate transported to the cytoplasm via 
folate receptors (and the anion carrier if the folate receptor and probenecid-
sensitive carrier work in tandem). T represents the amount of [3H]-5-MeH4folate 
transported to the cytoplasm only through the anion carrier without the help of 
folate receptors. Subscripts for E, R, T represent the conditions for the [3H]-5-
MeH4folate uptake. Experimentally measured values for uptake, the acid-
resistant fraction (AR) is the sum of E, R, and T. Therefore, we have the 
following equations for acid-resistant fractions measured under four different 
conditions; 
AR(a) = E(a) + R(a) + T(a) (i) 
AR(b) = E(b) + R(b) + T(b) 
AR(c) = E(c) + R(c) + T(c) 





Here, we could assume that the E(a) "" E(b) since probenecid does not affect 
endocytosis of folate receptors at low concentration and for short periods of 
incubation time (see Fig. 10). We also assume that E(c) "" E(d) "" 0 since the 
binding of 5-MeH.tfolate to folate receptor is almost completely blocked by excess 
folic acid (see Fig. 6). Then, we obtain the following equations by taking the 
differences between (i) and (ii) and between (iii) and (iv). 
AR(a)- AR(b) = R(a)- R(b) + T(a)- T(b) ----------------------- (v) 
AR(c)- AR(d) = R(c)- R(d) + T(c) - T(d) ----------------------- (vi) 
By taking the difference between (v) and (vi) we obtain equation (vii) as follows; 
{AR(a)- AR(b)}- {AR(c)- AR(d)} 
= {R(a)- R(b)}- {R(c)- R(d)} + {T(a)- T(b)}- {T(c)- T(d)} ----- (vii) 
which can be rearranged as follows; 
{AR(a)- AR(b)}- {AR(c)- AR(d)} 
= {R(a)- R(b)}- {R(c) - R(d)} + {T(a)- T(c)}- {T(b)- T(d)} ----- (viii) 
This equation can be further simplified as follows if we assume that R(c)=R(d)""O 
since folate receptors are almost completely blocked by folic acid and assume 
that T(a) "" T(c) and T(b) "" T(d) since folic acid has a very small affinity for the 
carrier and would not inhibit the transport of S-MeH4folate significantly; 
{AR(a)- AR(b)}- {AR(c)- AR(d)} 
"" {R( a) - R(b)} -------------------------------------------------------------- (ix) 
If probenecid inteferes with the translocation of [3H]-S-MeH4folate from the 
endosome to the cytoplasm, R(a) > R(b) and if not, R(a) = R(b). Therefore if 
{AR(a) - AR(b)} - {AR(c) - AR(d)} = 0, probenecid does not interfere with the 
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translocation of [3H]-5-Mel£1folate from the endosome to the cytoplasm, thereby 
proving that folate receptor and the anion carrier work independently (see Fig. 
17 A). If {AR(a) - AR(b)} - {AR(c) - AR(d)} > 0, probenecid interferes with the 
translocation of [3H]-5-MeH4folate from the endosome to the cytoplasm, 
suggesting that folate receptor and the anion carrier work in a dependent manner 
unless probenecid inteferes with the acidification of the endosome and inhibits 
the release of [3H]-5-Mel£1folate from the folate receptors into the endosome (see 
Fig. 17 B). If probenecid int.erferes with the acidification of the lumen of the 
endosome, {AR(a)- AR(b)} - {AR(c)- AR(d)} > 0 whether the folate receptor and 
the anion carrier work independently (Fig. 17 C) or not (Fig. 17 D) 
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Fig. 17 (A). If the folate receptor and the probenecid-sensitive anion carrier 
work independently and if probenecid does not interfere with the acidification 
of the lumen of caveola, {AR(a)- AR(b)}- {AR(c)- AR(d)} ""0. 








(c). With 100x excess 
folic acid 
(d). With 1 mM probenecid 
and 100x excess folic acid 
1-
T(c) 
R(c) ""' 0 
AR; acid-resistant fraction of [3 H]-S-MeH4folate 
E; eH]-S-MeH4folate in the caveola 
R; eH]-5-MeH 4folate transported to the cytoplasm 
by folate receptor 
T; eH]-S-MeH 4folate transported to the cytoplasm 
by the probenecid-sensitive anion carrier 
Bold arrows; transport of eH]-5-MeH 4folate. The length 
of the arrows represents the amount of [3H]-S-MeH 4folate 
transport in an arbitrary unit. 
142 
Fig. 17 (B). If the folate receptor and the probenecid-sensitive anion carrier 
work in tandem and if probenecid does not interfere with the acidification of 
the lumen of caveola, {AR(a)- AR(b)}- {AR(c)- AR(d)} > 0. 
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Fig. 17 (C). If the folate receptor and the probenecid-sensitive anion carrier 
work independently and if probenecid interferes with the acidification of the 
lumen of caveola, {AR(a) - AR(b)} - {AR(c)- AR(d)} > 0. 
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Bold arrows; transport of eH]-S-MeH 4folate. The length 
of the arrows represents the amount of eH]-5-MeH4folate 
transport in an arbitrary unit. 
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Fig. 17 (D). If the folate receptor and the probenecid-sensitive anion carrier 
work in tandem and if probenecid interferes with the acidification of the 
lumen of caveola, {AR(a)- AR(b)}- {AR(c)- AR(d)} > 0. 
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AR; acid-resistant fraction of eH]-5-MeH4folate 
E; eH]-5- MeH 4folate in the caveola 
R; eH]-5-MeH4 folate transported to the cytoplasm 
by folate receptor 
T; eH]-5-MeH 4folate transported to the cytoplasm 
by the probenecid-sensitive anion carrier 
Bold arrows; transport of eH]-5-MeH 4folate. The length 
of the arrows represents the amount of eH]-5-MeH 4folate 
transport in an arbitrary unit. 
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Fig. 18. Effect of probenecid and folic acid on uptake of S-MeH4folate at 50 
nM. 
(A) KB cells were incubated in 1ml fdDMEM containing 50 nM [3H]-5-
MeH4folate at 37 oc for 30 minutes in the absence (-Prob(OmM)) or presence 
(+Prob(lmM)) of 1 mM probenecid, or in the presence of 5 ).lM folic acid with 
(lOOxFol, +Prob.) or without (lOOxFol(S mcM)) 1 mM probenecid. Identical 
experiments were done at 0 °C for control. Uptake of [3H]-5-Mel-Ltfolate by KB 
cells was determined as described in MATERIALS AND METHODS. For each 
set, distributions of the acid-resistant fraction of [3H]-5-MeH4folate were 
obtained by averaging nine samples at 37 oc and three samples at 0°C. Acid-
resistant fractions at 0 oc experiments were subtracted from those at 37 oc. Error 
bars represent 95 % confidence limit. 
(B) (-P)-(+P) represents the difference between acid-resistant fractions (without 
100x folic acid) in the absence and presence of 1 mM probenecid. (100xF)-
(100x,+P) represents the difference between acid-resistant fractions in the absence 
and presence of 1 mM probenecid with 100x folic acid. Enhancement represents 
the difference between (-P)-(+P) and (lOOxF)-(lOOxF,+P). 
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Fig.lS (A) 
- Prob(OmM). + Prob(1 mM). 1 OOxFoi(S mcM) 1 OOxFol, + Prob. 
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Fig. 19. Transport systems regulating intracellular pH 
(a) C02 gas can diffuse in and out of the cell across the plasma membrane. It is 
dissolved in water and in equilibrium with proton and carbonate ion. 
(b) Na+ jH+ antiporter; A transporter normally exchanges extracellular Na+ for 
intracellular H+ in a 1:1 stoichiometry. It does not require HC03- or Cl-. It exists 
in a variety of vertebrate cells. 
(c) Na+-dependent Cl- I HC03- exchanger; A transporter, or family of 
transporters, that exchanges extracellular Na+ and HC03- (or a similar species) 
for intracellular Cl- and H+. It is found in several invertebrate cells and in 
certain cultured mammalian cells. 
(d) Proton pumps; ATP-driven H+ pumps play a central role in acid secretion 
by certain epithelia. 
(e) Na+ /HC03- cotransporter; A transporter which mediates net efflux of 
HC03- and Na+, giving rise to transcellular transport of HC03- in various 
organisms. 
(f) Na+-independent Cl- /HC03- exchanger; A transporter, or a family of 
transporters, which exchanges anions on opposite sides of the cell membrane in a 
stoichiometry of 1:1, and is inhibited or blocked by disulfonic stilbene 
derivatives. Probenecid was also found to block this transporter in Vero cells 
(ref. 76). Efflux of one molecule of carbonate generates one proton in the cell. 
All of the above transporters do not exist in one cell. 
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Fig. 19. Transport systems regulating intracellular pH 
Adapted from Madshus, I. H. (Biochem.]. (1988) 250, 1-8) 
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Fig. 20. Schematic diagram of Diphtheria toxin and Pseudomonas exotoxin 
action 
Receptor domain R of toxin (diphtheria toxin, DT or Pseudomonas exotoxin A, PE) 
binds to a cell surface receptor and is endocytosed via the coated pits. The low 
pH of the endosome and possibly other factors cause the toxin to unfold. Toxin 
is then proteolytically cleaved between translocation domain T and catalytic 
domain C. Cleavage is foll<?wed by reduction of the disulfide bond and the 
release of catalytic domain that translocates to the cytosol. In case of diphtheria 
toxin N-terminal 21 KDa catalytic domain is released from the transmembrane 
domain T. In case of Pseudomonas exotoxin A, C-terminal37 kDa is released. DT 
21 KDa fragment translocates into cytoplasm from the lysosome, whereas PE 37 
KDa travels to the Golgi apparatus and translocates into cytosol. In the cytosol 
DT Catalytic domain of each toxin adds an ADP ribosyl moiety to elongation 
factor-2 (EF-2). ADP ribosylated EF-2 can no longer support protein synthesis, 
leading to cell death. This was adapted from Pastan et al. (124). 
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Fig. 21. Schematic representation of the subunit composition of diphtheria 
toxin and Pseudomonas exotoxin A 
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Fig. 21 
























• N-ter: N-terminal GADDVVD- sequence; L: linker seq. 174-194 
T: transmembrane domain ; R: receptor domain ; C: catalytic domain 
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Fig. 22. Schematic diagram of drug delivery using folate receptor-mediated 
endocytosis of folate-conjugated liposomes Folate-conjugated liposome 
containing drug binds to the folate receptors associated with caveola (a). The 
liposome is endocytosed by cells (b) and fuses with the caveola (c) and the 
liposome contents are released into the cell cytoplasm (d). 
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Fig. 22. Schematic diagram of drug delivery using folate receptor-mediated 
endocytosis of folate-conjugated liposomes 
0 Folate-conjugated liposome 
F 
\ 
(a) binding to 
receptors ---
0 0 * 




I (c) Fusion of liposome t and endosome 
(d) release of liposome content 
into the cytoplasm 
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Chapter 3: Transport kinetics of oligonucleotides into 
reconstituted cellular nuclei 
and 
the effect of a nuclear localization signal peptide 
on the transport 
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SUMMARY Oligodeoxynucleotides designed to hybridize to specific rnRNA 
sequences (antisense oligonucleotides) or double stranded DNA sequences have 
been used to inhibit the synthesis of a number of cellular and viral proteins 
(Crooke, S. T. (1993) FASEB f. 7, 533-539; Carter, G. and Lemoine, N . R. (1993) 
Br. ]. Cacer 67, 869-876; Stein, C. A. and cohen, J. S. (1988) Cancer Res. 48, 2659-
2668). However, the distribution of the delivered oligonucleotides in the cell, i.e., 
in the cytoplasm or in the nucleus has not been clearly defined. We studied the 
kinetics of oligonucleotide transport into the cell nucleus using reconstituted cell 
nuclei as a model system. We present evidences here that oligonucleotides can 
freely diffuse into reconstituted nuclei. Our results are consistent with the 
reports by Leonetti et al. (Proc. Natl. Acad. Sci . USA, Vol. 88, pp. 2702-2706, April 
1991), which were published while we were carrying out this research 
independently. We also investigated whether a synthetic nuclear localization 
signal (NLS) peptide of SV 40 T antigen could be used for the nuclear targeting of 
oligonucleotides. We synthesized a nuclear localization signal peptide-
conjugated oligonucleotide to see if a nuclear localization signal peptide can 
enhance the uptake of oligonucleotides into reconstituted nuclei of Xenopus. 
Uptake of the NLS peptide-conjugated oligonucleotide was comparable to the 
control oligonucleotide at similar concentrations, suggesting that the NLS signal 
peptide does not significantly enhance the nuclear accumulation of 




Methods for delivery of oligonucleotides into cells Oligodeoxy-
nucleotides designed to hybridize to specific mRNA sequences (antisense 
oligonucleotides) or double stranded DNA sequences have been used to inhibit 
the synthesis of a number of cellular and viral proteins and therefore show 
promise as therapeutic agents to block the synthesis of specific proteins (reviews, 
1). It is believed that potential mechanisms of action of the oligonucleotides 
include inhibition of RNA systhesis and RNA processing in the cellular nucleus, 
degradation of mRNA by RNase H and translational arrest by inhibiting the 
interaction between ribosome and the mRNA in the cytoplasm (Fig. 1 A, ref. 1a). 
In order for the oligonucleotides to exert their effects on cellular activity, they 
must be delivered into the cellular cytoplasm and into the cellular nucleus. 
However, the efficiency of uptake of oligonucleotides by various cellular 
mechanisms may be too low (2). In order to circumvent this problem, different 
methods have been developed (1). Modifications of the backbone, base or sugar 
ring of the oligonucleotides (review 1), covalent conjugation of oligonucleotides 
to polylysine (3), cholesterol (4) or phospholipid (5), encapsulation of 
oligonucleotides in liposomes (6), and complex formation with positively 
charged liposomes (DOTMA liposomes, ref. 7) all enhanced cellular uptake of 
oligo-nucleotides. All of these methods enhance the delivery of oligonucleotides 
into the cytoplasm. However, the oligonucleotides are to exert their inhibitory 
effects in the cell nucleus, they must also enter the nucleus. In principle, 
oligonucleotides could enter the cell nucleus through the same entry routes as 
nuclear proteins or when nuclear membranes disassemble during mitosis. 
Transport of proteins into cell nucleus Studies have shown that the 
translocation of proteins and RNAs between the nucleus and the cytoplasm of 
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eukaryotic cells occurs through the nuclear pore complex (reviews 8-14, Fig. 1 B). 
Cell physiology experiments carried out with a number of different cells indicate 
that the pore complex has the properties of a molecular sieve containing an 
aqueous channel with a functional diameter of about 100 A (9, 10). Accordingly, 
small molecules or particles such as potassium ions, aminobutyric acid, sucrose, 
and inulin can passively diffuse across the pore complex into the nucleus (8) . 
Many nuclear proteins are too large to be accommodated by the apparent 
diameter of the pore. Most nuclear proteins with molecular weights greater than 
20 kD, as well as some small nuclear proteins, are transported into the nucleus 
through nuclear pores by a process that requires the recognition of a peptide 
signal sequence (13, 14). Various studies have shown that the nuclear proteins 
have one or two short nuclear localization signal (NLS) peptides (13) and these 
signal peptides are recognized by the nuclear localization signal binding proteins 
in the cell cytoplasm or by the nuclear pore complex for nuclear transport (11, 14, 
Fig. 1 C). Nuclear protein import, which requires ATP hydrolysis and is 
temperature-dependent (15), involves at least two steps (16-18): binding of the 
signal sequence at the recognition site, possibly to nuclear pore-associated fibrils 
(19, 20), followed by slower, energy-dependent translocation through nuclear 
pores (16-18) . 
Nuclear localization sequences in nuclear proteins Dingwall et al. (21) 
found that when the carboxy terminal third of nucleoplasmin (125 kD), a 
Xenopus nuclear protein, was removed by protease digestion, the amino terminal 
core was unable to enter the nucleus. The separated carboxy tail of 
nucleoplasmin, in contrast, quickly entered the nucleus. It has since been shown 
that complexing nucleoplasmin to large nonnuclear molecules such as 
immunoglobulin, IgG (22), an algal protein, phycoerythrin (23), or even to large 
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gold particles (24) confers rapid entry into the nucleus. Feldherr (24) injected 
nucleoplasmin-coated gold particles into Xenopus oocytes, and observed that 
particles up to 200 A in diameter enter the nucleus through the central channel 
of the pore, whereas particles coated with proteins lacking signal sequences 
remain in the cytoplasm. Nuclear localization signals have been analyzed for a 
number of proteins in viruses, yeast, Xenopus and mammals (13) . The signal 
sequences frequently contain short regions of basic amino acids containing 
proline resides, but not all are of this type (13). 
The most extensively studied localization signal peptide is that of the large 
T antigen of SV 40 (simian virus 40). The 94 kD T antigen polypeptide becomes 
highly concentrated in the nucleus following synthesis in the cytoplasm. The T 
antigen localization signal peptide comprises a stretch of 7 amino acids 
surrounding the 128th amino acid residue in the T antigen polypeptide with the 
sequence 126pro-lys-128lys-lys-arg-lys-132val (25). T antigen transport is 
abolished when this region is deleted, or when certain amino acid substitutions 
are induced (25). The lysine residue 128 is particularly critical; when this amino 
acid is changed to asparagine, as found in a naturally occurring variant of the T 
antigen (26), or to threonine (25), the resulting protein remains in the cytoplasm. 
When cells express chimeric genes consisting of the sequence of the wild-type SV 
40 T antigen localization signal peptide coupled to the amino terminus of the 
gene for ~-galactosidase (116 kD) or pyruvate kinase (58 kD), the resultant 
chimeric proteins accumulate at high levels in the nucleus (27). In contrast, the 
proteins remain in the cytoplasm when the signal sequence is modified at lysine 
128 or with no added signal sequence. Most strikingly, when synthetic peptides 
containing the wild-type localization sequence are chemically coupled to 
nonnuclear proteins (- 10 peptides per protein) such as ovalbumin (43 kD; 
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diameter 54 A, ref. 28), bovine serum albumin (67 kD, diameter 70 A, ref. 28, 29), 
immunoglobulin G (150 kD, 35x35x140 A, ref. 28, 29) or ferritin (465 kD; diameter 
94 A, ref. 28), the resulting conjugates accumulate rapidly in the nucleus. The 
rate of transport is influenced by the number of peptides per cytoplasmic protein 
and to some extent by the size of the protein (28). The presence of excess free 
signal peptide reduces nuclear transport of peptide-protein conjugates (29), 
suggesting the possible saturation of a receptor protein within the pore. 
Purpose of this study Even though many methods have been developed to 
target nucleic acids into cells, it has not been clearly shown that the delivered 
oligonucleotides could reach the cell nucleus until recently (30). It is possible for 
the short oligonucleotides to diffuse into the cellular nucleus through the nuclear 
pore complexes (8). Alternatively, the oligonucleotides could interact with 
genomic DNA when the nuclear membranes disassemble during cellular division 
(31). Therefore, we s tudied the kinetics of oligonucleotide transport into the cell 
nucleus using reconstituted nuclei (32) as an in vitro model system to answer this 
question. We also investigated whether a synthetic nuclear localization signal 
peptide of SV40 T antigen could be used for nuclear targeting of 
oligonucleotides. We synthesized a nuclear localization signal peptide-
conjugated oligonucleotide in order to determine whether the nuclear 
localization signal peptide could enhance the uptake of oligonucleotides into the 
reconstituted nuclei of Xenopus. Our results were consistent with the reports by 
Leonetti et al. (30), which was published while we were doing this research 
independently. 
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MATERIALS AND METHODS 
Materials 
N-E-FMOC-N-a-Boc-L-lysine was purchased from Bachem, Inc., Torrance, 
CA. Amino link 2 (Fig. 2) was purchased from Applied Biosystems. 
Maleimidobenzoyl succinimide (MBS) was purchased from Pierce Chemical 
Company. Sephadex G-25 (fine) and fluorescein isothiocyanate (FITC) were 
purchased from the Sigma Chemical Company. Tetramethylrhodamine-6-
isothiocyanate (TRITC) was purchased from Molecular Probes, Inc. Xenopus 
laevis eggs and sperm nuclei were the gifts of professor William Dunphy in the 
Division of Biology at the California Institute of Technology. 
Synthesis of an olgonucleotide containing an aminohexyl linker A 20-
mer oligonucleotide with the sequence ofCGACCGATGC-CCTIGAGAGC (5'-3', 
1721th-1740th nucleotide sequence of a plasmid, sisCAT) was synthesized using 
phosphoramidite chemistry (33, 34) in the laboratory of Dr. Suzanna Horvath at 
California Institute of Technology. Amino link 2 (see Fig. 2, Applied Biosystems) 
was coupled to the 5'-end and an aminohexyl containing oligonucleotide was 
prepared. 
Solid-phase synthesis of nuclear localization signal peptides 
(a) Synthesis of a nuclear localization signal peptide (peptide1); A synthetic 
nuclear localization signal peptide (Pro-Lys-Lys-Lys-Arg-Lys-Val-Glu-Asp-Tyr-
Cys, peptide 1) was prepared using tBOC chemistry (35) in the laboratory of Dr. 
Suzanna Horvath at the California Institute of Technology. 
(b) Synthesis of fluorescein labeled nuclear localization signal peptide (F-peptide2); 
The fluorescein isothiocyanate (FITC)-conjugated peptide (FITC-Lys-Pro-Lys-
Lys-Lys-Arg-Lys-Val-Glu-Asp-Tyr-Cys, F-peptide 2, see Fig. 3.) was prepared 
using the modified procedures of Halleck et al. (36). A peptide, Lys-Pro-Lys-Lys-
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Lys-Arg-Lys-Val-Glu-Asp-Tyr-Cys was synthesized on resin by a solid-phase 
synthesis using 2-chlorobenzyloxycarbonyl protection of the £-amino groups of 
internallysines and 9-fluorenylmethyloxycarbonyl (FMOC) protection of theE-
amino group of the N-terminallysine in the laboratory of Dr. Suzanna Horvath 
at the California Institute of Technology. After synthesis of the peptide, the 
FMOC group was removed by washing the resin with 50% (vol/vol) piperidine 
in dichloromethane manually. The deprotected £-amine group of theN-terminal 
lysine was labeled with fluorescein by treating the resin (about 200 mg) 
consecutively with fluorescein isothiocyanate (FITC, 50-60 mg) three times for 
several hours. Peptides were deprotected and released from the reisin using 
hydrofluoric acid. Fluorescein isothiocyanate-conjugated peptides (F-peptide 2) 
were purified by reverse-phase HPLC and the molecular weights of the peptides 
were verified by mass spectrometry. 
Conjugation of peptides to bovine serum albumin The synthetic nuclear 
localization signal peptides (peptide 1 and F-peptide 2) were coupled to bovine 
serum albumin (BSA) using a bifunctional cross-linking reagent, 
maleimidobenzoyl succinimide (MBS) according to the modified procedures of 
Lanford et al.(28, Fig. 4). The maleimidobenzoyl succinimide (MBS) solution (5 
mg in 0.5 ml DMF) was added to the bovine serum albumin (BSA) solution (10 
mg in 2 ml phosphate buffered saline, pH 7.4) dropwise and allowed to react for 
1 hour at room temperature. Bovine serum albumin which had been modified 
with maleimidobenzoyl succinimide (MBS) was purified by gel-filtration 
chromatography using a Sephadex G-25 column (1.5x20 em) with 0.1 M sodium 
phosphate solution (pH 6.0) as the elution buffer. Fractions containing the 
modified BSA were collected and concentrated by centrifugation at 3,000 rpm for 
15 minutes in a GSA rotor (Beckman) using a Centriprep-30 concentration device 
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(Amicon). 5 mg of signal peptide (peptide 1) was dissolved in 1 ml volume of 0.1 
M sodium phosphate buffer (pH 6.0) and was immediately added to the MBS-
modified BSA solution dropwise and the reaction mixture incubated at room 
temperature for 1 hour. The peptide-conjugated BSA was purified by gel-
filtration chromatography using 0.1 M NI-4HC03 as the elution buffer on a 
Sephadex G-25 column (1.5x20 em). Fractions of eluted solution containing 
peptide-conjugated BSA were collected, washed twice by centrifugation with 15 
ml 0.1 M NH4HC03 solution in Centriprep-10 concentrator and lyophilized. 
Peptide-BSA conjugates were analysed by amino acid analysis to determine the 
average number of peptide ligands per BSA molecule. 
Similarly, FITC-labeled nuclear localization signal peptide (F-peptide 2, 0.7 
mg/0.5 ml DMF) was conjugated to BSA (about 10 mg in 1 ml 0.1 M sodium 
phosphate buffer, pH 6.0) after modification with MBS. The number of 
conjugated peptides per BSA molecule was determined by measuring the 
absorbance of the fluorescein groups in the peptide-BSA conjugate at 494 nm 
using the FITC-labeled peptide as a standard. The protein concentration was 
determined using the Bio-Rad protein assay method with BSA as a standard. 
Conjugation of oligonucleotide to FITC-labeled peptide (F-peptide2) 
FITC-conjugated peptides containing a cysteine residue were coupled to 
oligonucleotides containing an aminohexyl group using maleimidobenzoyl 
succimide (Fig. 4). Oligonucleotides containing an aminohexyl group (55 !J.l of 
0.545 mM in 0.1 M sodium borate solution, pH 7.0) were mixed with MBS 
solution (110 !J.l of 10 mg/ml N, N-dimethylformamide solution). The reaction 
was carried out for 45 minutes at room temperature. At the end of the reaction, 
335 !J.l of 0.1 M sodium borate solution was added to the reaction mixture 
followed by 1 ml cold ethanol and the mixture then incubated on dry ice-chilled 
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ethanol for 10 min to precipitate DNA. Precipitated oligonucleotides were 
pelleted by centrifugation at 12,000 g for 10 min at 4 °C. The oligonucleotide 
pellet was dissolved in 100 j.tl Tris-EDTA solution (TE, 10 mM Tris, 1 mM EDTA, 
pH 8.0) and the solution was centrifuged once more for 5 min to remove 
insoluble material. The supernatant solution containing modified 
oligonucleotides was collected after centrifugation. To this solution, a 9.1 j.tl 
volume of 3M sodium acetate solution (pH 5.2) was added followed by two 
volumes of cold ethanol and incubation as described above for ethanol 
precipitation. Oligonucleotide precipitates were collected again by 
centrifugation. An additional ethanol precipitation and centrifugation was 
performed to further purify the oligonucleotides. The oligonucleotide pellet was 
lyophilized overnight and was dissolved in 50 J.ll TE buffer to a final 
concentration of 0.22 mM. The concentration of the oligonucleotide solution was 
determined by the measurement of absorbance at 260 nm and the use of the 
molar extinction coefficient of 2xl05 M-lcm-1 for the 20-mer oligonucleotide. The 
FITC-labeled peptide (F-peptide 2) was dissolved in 250 J.ll of 50 mM Tris (pH 
7.4) to a final concentration of 1.4 mM. The oligonucleotides modified with 
maleimidobenzoyl succinimide were added to the FITC-peptide solution and the 
reaction mixture was incubated for 3 hours at room tmperature. This coupling 
reaction resulted in a yellow viscous material. This was dissolved in the TE 
buffer and purified by seven consecutive ethanol precipitations. In order to 
verify the conjugation of FITC-labeled peptide (F-peptide 2) and the 
oligonucleotide, a larger scale synthesis was performed and the products were 
analysed by polyacrylamide-gel electrophoresis (37). 
Labeling of peptidel, BSA and peptidel-conjugated BSA with fluorescein 
isothiocyanate (FITC) or tetramethylrhodamine isothiocyanate (TRITC) (see 
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Fig. 5) 5-10 mg/ml protein solutions were prepared in deionized water. 0.2-2.0 
mg/ml FITC solution was prepared in 0.2 M sodium carbonate buffer (pH 9.5). 
The reaction was started by mixing the two solutions and the reaction allowed to 
continue for 2 hours at room temperature. FITC-labeled proteins were purified 
by Sephadex G-25 gel filtration chromatography using 0.2 M sodium carbonate 
buffer. Protein concentrations were determined using the Bio-Rad protein assay 
solution. The number of fluorescein groups per protein molecule was 
determined by measuring the absorbance of fluorescein at 494 nm using the 
FITC-labeled peptide 2 as a standard. Protein concentrations were determined 
using Bio-Rad protein assay solution. Peptide1-conjugated BSA was labeled with 
TRITC, similarly. The number of TRITC per protein molecule was not 
determined. 
Labeling of oligonucleotide with FITC or TRITC (see Fig. 5 and 6) A 
volume of 40 j..tl of the oligonucleotide solution (0.70 mM in 0.2 M sodium 
carbonate buffer (pH 9.5)) was added to 120 j..tl FITC solution (12.8 mM in the 
same buffer) . The reaction mixture was incubated at room temperature for 2 
hours . The FITC-labeled oligonucleotide was purified by two consecutive 
ethanol precipitations, desalted using SEP-PAK C18 cartridges (Millipore) and 
lyophilized. 
Similarly, oligonucleotide samples were labeled with TRITC in the 0.2 M 
sodium bicarbonate buffer. 10 j..tl of oligonucleotide solution (1.76 mM) was 
added to 90 ml of TRITC solution (1.44 mM) and allowed to react for 3 hours. 
TRITC-labeled DNA was purified by 5 repeated ethanol precipitations followed 
by desalting using SEP-PAK C18 cartridges (Millipore). Approximate 
concentrations of the oligonucleotide solutions were determined by measuring 
the absorbance of diluted oligonucleotide solutions at 260 nm. 
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Reconstitution of nuclei using Xenopus laevis egg extracts Transport 
competent nuclear membranes were reconstituted using Xenopus egg extracts 
and Xenopus sperm nuclei as described in the Appeidix. D (references 32, 38) 
Nuclear transport of proteins and oligonucleotides Appropriate 
concentrations of fluorescently labeled proteins or oligonucleotides were added 
to reconstituted nuclei (28, 29). After incubation for appropriate periods of time 
and temperatures, aliquots of the assay solution were mixed with Hoechst 33258 
dye in a fixation buffer to stain sperm DNA (see Appendix. D) and the 
fluorescence of the sperm DNA or added compounds were observed with a 
fluorescence microscope (Zeiss Axioplan). 
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RESULTS 
Synthesis of peptides, BSA-peptide conjugates, oligonucleotide-peptide 
conjugate and fluorescent labeling of peptide 1, BSA, BSA-peptide conjugate 
and oligonucleotides The approximate chemical formulae and concentrations of 
the compounds used in the transport experiments are summarized in Table 1. A 
typical mass spectrum of FITC-labeled peptide (F-peptide 2) is shown in Fig. 7. 
The major peak at 1912 (m/ e) indicates that we obtained a peptide which was 
labeled with FITC as desired. Conjugation reactions of peptides to BSA resulted 
in BSA-conjugates with 10-20 peptides per molecule of BSA. Conjugation of 
fluorescein-labeled peptide (F-peptide 2) to DNA was demonstrated by 
polyacrylamide-gel electrophoresis. 
Reconstitution of the functional nuclear envelope and transport of the 
nuclear localization signal peptide-conjugated BSA into reconstituted nuclei 
Time-dependent morphological changes of Xenopus sperm DNA and nuclear 
membranes are shown in Fig. 9. Initially, sperm chromaatin showed compact 
and elongated structures and the nuclear membranes were not visible. In about 
10-20 min, the sperm chromatin became decondensed and in 30-40 min the 
nuclear membranes became clearly visible. This stage corresponds to interphase 
in the cell cycle (31, 32) . In order to see if the reconstituted nuclei were active in 
nuclear protein transport, we added FITC-labeled nuclear localization signal 
peptide-conjugated BSA [F-(B-P1)] to reconstituted nuclei and nuclear 
fluorescence was observed as indicated in Fig. 10 A. At time zero, FITC-labeled 
nuclear localization signal peptide-conjugated BSA molecules [F-(B-P1)] had not 
accumulated in the nuclei. In about 30 min of incubation at room temperature 
the concentration of the protein in the nuclei became clear. After 60 min the 
fluorescence of the nuclei became more intense, suggesting that the FITC-labeled 
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nuclear localization signal peptide-conjugated BSA molecules were transported 
into the nuclei and concentrated. On the contrary, FITC-labeled BSA molecules 
(F-BSA) did not accumulate in the nuclei (Fig. 10 B). These results confirmed the 
previous observation that the nuclear localization signal peptides of SV 40 T 
antigen confer the translocation of large molecules to which the peptides are 
conjugated (28, 29). However, the synthetic nuclear localization signal peptides 
labeled with fluorescein isothiocyanate (F-peptide 1) did not accumulate in the 
nuclei (Fig. 10 B). Lobl et al. (39) have reported that synthetic nuclear localization 
signal peptides of SV 40 which were labeled with a small fluorescent probe 
(monobromobimane) also did not accumulate in cell nucleus. Our results are 
consistent with their finding. The signal peptide can probably diffuse in and out 
of the nuclei freely via the nuclear pore complex since the size of the peptide is 
small. Interestingly, reconstituted nuclei with apparent nuclear membranes were 
not always active at protein import as shown in Fig. 10 A (60 min at room 
temperature). We counted the number of reconstituted nuclei with membranes 
and the number of transport competent nuclei simultaneously using different 
light filters with a fluorescence microscope. Typically about 50 percent of the 
reconstituted nuclei were active in protein import and the percentage varied 
slightly from experiment to experiment. 
Accumulation of oligonucleotides in the reconstituted nuclei by free 
diffusion Transport experiments with FITC-labeled oligonucleotides showed 
that oligonucleotides could be associated with the reconstituted nuclei even 
though the oligonucleotides did not have a signal peptide (Fig. 11). This 
fluorescence was not due to Hoechst 33258 dye since the fluorescence of the 
Hoechst dye was not detectable through the light filter used for fluorescein (Fig. 
10 B). Similar results were obtained from the experiments carried out with 
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tetramethylrhodamine isothiocyanate-labeled oligonucleotide (R-DNA, Fig.12). 
The fluorescence of the nuclei bacame more intense as the incubation time 
increased (see 120 min incubation in Fig. 12). In order to determine whether the 
time-dependent nuclear accumulation of oligonucleotides was related to the 
activity of protein uptake by the reconstituted nuclei, we carried out an uptake 
experiment (fig. 13) with both fluorescein labeled BSA-peptide 1 conjugates [F-
(B-P1)] and TRITC-labeled oligonucleotides (R-DNA). The association of 
oligonucleotide with transpo~t-competent nuclei was clearly shown after 90 and 
120 min incubation. The rhodamine fluorescence was not due to fluorescein 
since the fluorescence of fluorescein labeled BSA-peptide 1 conjugates [F-(B-P1)] 
through the light filter for rhodamine emission was undetectable (third row of 
Fig. 13). The association of the oligonucleotides with the nuclei was also shown 
in the presence of unlabeled BSA-peptide 1 conjugate (fourth row of Fig. 13). 
These data suggest that the association of oligonucleotides with the reconstituted 
nuclei is related to active protein uptake by the nuclei. It might be possible that 
transport-competent nuclei could actively accumulate proteins to which the 
oligonucleotides bind after diffusion into the nuclei via the nuclear pore complex. 
If the oligonucleotides could not diffuse into the nuclei, they could bind to the 
nuclear proteins in the incubation media and later are transported into the 
reconstituted nuclei along with the proteins. In order to define further the 
mechanism of nuclear association of oligonucleotides, we carried out a time-
differential dual label experiment (Fig. 14). Reconstituted nuclei were incubated 
with fluorescein-labeled BSA-peptide 1 conjugate [F-(B-P1)] for 60 min in order 
to discern transport-competent nuclei. At the end of incubation, the 
reconstituted nuclei were chilled on ice for 20 min to stop the transport process. 
After this, the medium containing reconstituted nuclei was divided into two 
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fractions . One was incubated on ice for 5 min and the other was incubated at 
room temperature for 5 min. At the end of this incubation, TRITC-labeled 
oligonucleotides (R-ONA) or tetramethylrhodamine labeled BSA-peptide 1 
conjugate (R-(B-Pl)) were added to each fraction and the fluorescence associated 
with the nuclei was observed. Our data showed that the association of 
oligonucleotides with transport-competent nuclei occurred immediately at both 
room temperature and 0 ac (pictures in the 1st and 2nd row in Fig. 14). The 
rhodamine fluorescence was not due to the background fluorescence of 
fluorescein (Pictures in the 3rd row of Fig. 14). The rhodamine fluorescence of 
tetramethylrhodamine labeled BSA-peptide 1 conjugate [R-(B-P2)] was not 
observed immediately after addition to the nuclei which had accumulated 
fluorescein-labeled BSA-peptide 1 conjugate [F-(B-Pl)] (pictures in the 4th row of 
Fig. 14) . However, the rhodamine fluorescence of tetramethylrhodamine labeled 
BSA-peptide 1 conjugate [R-(B-P2)] was detectable after further incubation for 90 
min. It was not clear whether BSA-peptide 1 conjugates accumulated in the 
reconstituted nuclei enhanced the accumulation of the oligonucleotides slightly. 
However, it was clear that the nuclear accumulation of the oligonucleotides was 
not entirely due to BSA-peptide 1 conjugates since the association of 
oligonucleotides with nucleotides was observed in experiments performed 
without BSA-peptide 1 conjugates (Figs. 11 and 12). These results showed that 
small oligonucleotides freely diffused into the reconstituted nuclei and stayed 
inside the nuclei whereas large proteins were only slowly transported to the 
nuclei via a process requiring a nuclear localization signal peptide. 
Effect of the nuclear localization signal peptide on the nuclear 
acumulation of oligonucleotides As shown in Fig. 15, the nuclear localization 
signal peptide did not change the nuclear accumulation of oligonucleotides 
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significantly. At similar concentrations of oligonucleotide, the accumulation of 
oligonucleotides (F-DNA) was comparable to that of fluorescein labeled peptide 
(peptide 2)-conjugated oligonucleotide [(F-P2)-DNA]. The activity of the FITC-
labeled nuclear localization signal peptide (peptide 2) was compared to that of 
FITC peptide 1 in Fig. 16. According to our observations, for similar sized nuclei, 
the fluorescence intensity of nuclei which were incubated with fluorescein-
labeled BSA-peptide 1 conjugate [F-(B-P1)] for 30 min was comparable to that of 
nuclei which were incubated in the presence of BSA conjugated to FITC-peptide 
2 [(F-P2)-B]. The number of fluoresceins on one molecule of BSA-peptide 1 
conjugate [F-(B-P1)] was about 5 (see Table 1) whereas that for BSA conjugated to 
FITC-peptide 2 [(F-P2)-B] was about 10. Therefore, two nuclei with similar size 
and similar fluorescence intensity accumulated the two protein conjugates, i.e., 
BSA-peptide 1 conjugate [F-(B-P1)] and BSA conjugated to FITC-peptide 2 [(F-
P2)-B] with a concentration ratio of 2:1. In other words, the concentration of 
BSA-peptide 1 conjugate (F-(B-P1)) in a nucleus after 30 min incubation was 
twice as high as the concentration of BSA conjugated to FITC-peptide 2 [(F-P2)-B] 
in a nucleus with similar size. Therefore, the ratio of rate of accumulation of 
BSA-peptide 1 conjugate [F-(B-P1)] to that of BSA conjugated to FITC-peptide 2 
[(F-P2)-B] in nuclei of comparable size was approximately (2/30)/(1/160)===10 
assuming that the uptake of the proteins into the nuclei linearly increased during 
the measurement. Considering the fact that the initial concentration of BSA-
peptide 1 conjugate [F-(B-P1)] was about one half of the concentration of BSA 
conjugated to FITC-peptide 2 [(F-P2)-B], the ratio of rate of accumulation of BSA-
peptide 1 conjugate [F-(B-P1)] to that of BSA conjugated to FITC-peptide 2 [(F-
P2)-B] was approximately 20. The number of signal peptides per BSA-peptide 1 
conjugate [F-(B-P1)] was about 14 and the number of signal peptides per BSA 
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conjugated to FITC-peptide 2 [(F-P2)-B] was about 10. Taking all these results 
into consideration, it can be concluded that the nuclear localization activity of 
FITC-labeled peptide 2 was significantly reduced compared to peptide 1 
(approximately (1/20)x(14/10)""1/14 assuming that the rate of uptake of BSA is 
directly proportional to the number of conjugated signal peptides). The bulky 
fluorescein appears to interfere with the binding of the signal peptide to its 
receptor. However, the activity was not completely abolished. This residual 
activity of fluorescein labele~ nuclear localization signal peptide (F-peptide 2) 
was still able to confer the translocation of large BSA molecules into the nuclei. 
However, the accumulation of oliginucleotide was not affected much by the 
conjugation of the signal peptide (F-peptide 2). This could be partly due to the 
small size of the oligonucleotide-peptide conjugates. If the oligonucleotide-
peptide conjugate is considered as an elongated rod, its diameter may be much 
smaller than the functional diameter of the pore of the nuclear pore complex. 
Summary of results Our experimental data were summarized in Table. 2. 
Our experimental data confirmed the previous observation that large protein 
molecules require nuclear localization signal peptides for nuclear transport 
whereas small molucules freely diffuse into the nuclei. 
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DISCUSSION 
Our experimental data suggested that oligonucleotides can freely diffuse 
into the reconstituted nuclei through the nuclear pore complex and that the 
oligonucleotides can accumulate in the nuclei by binding to presently unknown 
nuclear factors. These binding sites could be any DNA binding proteins in the 
nuclei. This interpretation is consistent with the findings by Leonetti et al. (30) . 
They microinjected antisense oligonucleotides (15-mers) conjugated with 
fluorescein isothiocyanate or tetramethylrhodamine isothiocyanate into the 
cytoplasm of rat embryo fibroblast cells (REF-52). They observed that the 
fluorescently tagged oligonucleotides were translocated and concentrated in the 
nuclei within one minute after microinjection. Using photoaffinity labeling and 
polyacryl amide gel-electrophoresis, they also showed that primarily four 
nuclear proteins with molecular weights ranging from 36 kD to 50 kD were 
crossed-linked to photosensitive radioactively labeled oligonucleotides 
(bromo uri dine containing oligonucleotide) . 
We do not know the distribution of the oligonucleotides in the nucleus in 
detail in our system. We used reconstituted nuclei for transport experiments and 
we do not know clearly whether in these nuclei intranuclear organelles such as 
nucleoli were reconstituted faithfully . We usually observed that the 
oligonucleotides were distributed evenly in the reconstituted nuclei. Since the 
nucleolus does not have a membrane (40), the targeting of oligonucleotides to the 
nucleolus might be possible. Then, blocking of RNA processing in the nucleolus 
as well as in the transcription of genes from genomic DNA might be possible 
using ther oligonucleotides, which would result in inhibition of cellular activity 
(41). 
175 
Our data showed that nuclear localization by the signal peptide does not 
enhance the accumulation of oligonucleotides in the nuclei significantly. This 
could be due to the reduced activity of the signal peptide or due to the small size 
of the conjugate. Further studies will be necessary to resolve this question 
unequivocally. Originally, we intended to use the signal peptide to target 
oligonucleotides to cell nuclei. Our results suggest that this might not be 
necessary since oligonucleotides alone can diffuse into and accumulate in the 
nuclei. In summary, oligonucleotides could exert their therapeutic activity both 
in the cytoplasm and in the cellular nucleus once delivered into the cell 
cytoplasm by the methods mentioned above (3-7) since oligonucleotides can 
freely diffuse into the nucleus through nuclear pore complexes. 
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IMPLICATIONS AND FUTURE RESEARCH 
In this study we showed that short oligonucleotides can freely diffuse into 
the nuclei reconstituted from Xenopus egg extracts and Xenopus sperm nuclei. It 
has been reported that the diameter of the nuclear pore complex varies slightly 
from species to species. By determining the size of proteins, dextrans, or gold 
particles that can enter the nucleus when injected into the cytoplasm, the 
apparent pore diameter has been estimated to be 90 A for Xenopus oocytes and 
Drosophila salivary gland nuclei, 100-110-A for hepatocytes and hepatoma cells 
and 120 A for amoebae (9). Judging from the diameters of the nuclear pores from 
these organisms, it is likely that small oligonucleotides freely diffuse into the 
nuclei of other types of cells as well as the Xenopus reconstituted nuclei. 
We used oligonucleotides with only 20 nucleotides. It would be interesting 
to determine the limit of size of DNAs that can diffuse into nuclei. It would be 
interesting to determine whether large DNA molecules such as bacterial 
plasmids can diffuse into the cell nuclei. If it turns out that large bacterial 
plasmids can not diffuse into cell nuclei freely, it would imply that plasmid DNA 
molecules gain access to genomic DNA in a cell cycle-dependent manner. It is 
possible that large exogenous DNA molecules are enclosed in cell nuclei when 
the nuclear membranes disassemble and reassemble during cell division (31). 
Recently, Kaneda et al. (42) reported that when the plasmid DNA and 
nuclear protein of rat cells were encapsulated in vesicle complexes (DNA-loaded 
phospholipid vesicles with gangliosides were fused with Sendai virus and the 
resulting fusion products were fused with red blood cell ghosts.), and 
cointroduced into nondividing cells in rat liver by injection into the portal vein of 
adult rats, the plasmid DNA was carried into the liver cell nuclei efficiently by 
the nuclear protein. Wienhues et al. (43) reported that reconstituted DNA with 
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the major core protein VII of adenovirus type 2 or protamine from salmon 
sperm was rapidly transported into the cell nuclei. These examples showed that 
large DNA molecules can be carried into cell nuclei using the mechanism of 
nuclear protein import. Although short oligonucleotides did not require any 
signal peptide for nuclear accumulation, large DNA molecules or other 
therapeutic molecules could be targeted into cell nucleus using nuclear 
localization signal peptides in combination with appropriate methods for 
intracellular administration as described in the Introduction section. 
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Table 1. Summary of chemical formulae and concentrations of stock solutions 
used in the experiments 
Sample stock Concentration Chemical 
!lg/111 11M formula 
lx B-PI 1.93 29.1 (Pl)l3.8BSA 
lx F-Pl 0.269 ± 0.005 192.90 Fo.23Pl 
lx F-BSA 0.427 ± 0.013 6.44 F3.4BSA 
O.lx F-(B-P1) 0.318 ± 0.006 3.73 Fs.3(P1h3.8BSA 
0.1x R-(B-P1) 0.202 ± 0.006 2.37 Rx(P1)n.8BSA 
1x (F-P2)-B 0.710 ± 0.001 8.43 (F-P2)9.sBSA 
1xF-DNA 3.96 594 Fo.42DNA 
1xR-DNA 1.67 248 RxDNA 
1x (F-P2)DNA 2.62 312 (F-P2)}DNA 
Abbreviations: 
B; BSA 
F; fluorescein isothiocynate (FITC) 
R; tetramethylrhodamine isothiocyanate (TRITC) 
Rei. Ab 






P1; peptide with the sequence of PKKKRKVEDYC(N to C terminal) 
P2; peptide with the sequence of KPKKKRKVEDYC(N to C terminal) 
F-P2; P2labeled with fluorescein at the £-amine of the N-terminallysine 
B-P1; Bovine serum albumin labeled with P1 
(F-P2)-B; Bovine serum albumin labeled with F-P2 
DNA; DNA with an aminohexyllinker at 5'-end 
F-or R-ONA; DNA labeled with FITC or TRITC 
x; unknown 
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Table. 2. Summary of transport assay 
Sample Transport at 





DNA +* +* 







probably free diffusion 
* Reconstituted nuclei active for BSA-Peptide1 conjugate were always positive 
for DNA accumulation. Nulcei inactive for BSA-Peptide 1 conjugate were either 
positive or negative for DNA accumulation. +,observed; -,not observed 
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Fig. 1. (A) Schematic diagram of potential sites of antisense oligonucleotide 
action 
RNA processing and the potential actions of oligonucleotides are shown. 
Adapted from Crooke, S. T. (Faseb ]. 7, 533-539, 1993) 
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Transcription --- Transcriptional Arrest 
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Fig. 1. (B) Nuclear import and export 
NLS, nuclear localization signal peptide; NBP, NLS-binding protein; CLS, 
cytoplasmic localization signal; RNP, ribonuclear protins; snRNP, small nuclear 
RNP. This was adapted from Nigg et aL (Cell 66, 15-22, 1991). 
Cytoplasm 
,'h.-:.o-_q·~········· ... -: 
r nuclear membrane 
Inner nuclear 
membrane 




) ~CLS ~ ~-D-iff-u-si-on--. 
( Ions, Metabolites, 
Small Proteins ) 
186 
Fig. 1. (C) Models for protein import into the nucleus 
NLS, nuclear localization signal peptide; NPC, nuclear pore complex. Adapted 
from Stochaj, U. et al. (Eur . f. Cell Bioi. 59, 1-11, 1992) 
1) Binding of nuclear proteins to NL5-receptors 
Cytoplasm Nucleoplasm 
2) Association with the nuclear pore complex 
Cytoplasm Nucleoplasm 
3) Translocation across the nuclear envelope 
A) Release and import ( ( 
Cytoplasm +ATP ~ Nucleoplasm 
~-~ 






Fig. 2. Synthesis of aminohexyl containing oligonucleotide 










Aminolink 2- Oligonucleotide 
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Fig. 3. Schematic diagram of the synthesis of FITC-labeled peptides 
Peptides were synthesized on solid-support. The protecting groups for the side 
chains are shown in abbreviations: Meb, S-4-rnethylbenzyl; 2-Br-CBZ, 2-
brornobenzyloxycarbonyl; Bz, benzoyl; 2-Cl-CBZ, 2-chloro benzoyloxycarbonyl; 
Tos, p-tolunesulfonyl; FMOC, 9-fluorenylrnethyloxycarbonyl; Boc, t-
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Fig. 4. Conjugation of nuclear localization signal peptide to BSA or 
oligonucleotide using a bifunctional cross-linking reagent, MBS 
DNA, A A -"' 
V v v 'NH2 
or Protein 
+ 
Q oD~o II -N-O-C ~ ~ MBS 
0 
~S-Peptide 
0~ 0 DNA, A A -"' II -
v v v 'NHC ~ ~ 
or Protein 
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Fig. 7 Mass spectrum of FITC-labeled peptide 2 
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Fig. 8. Amino acid analysis of peptide 1-conjugated BSA 
(A) Five different preparations of BSA-peptide 1 conjugates were analysed by 
amino acid analysis. The amino acid composition of BSA from amino acid 
analysis was used as standard. The differences between the number of amino 
acids of BSA-peptide 1 conjugates and that of control BSA were shown for the 
amino acids occurring in peptide 1. The number of lysines was divided by four 
to calculate the number of peptides which were conjugated to BSA (B) The 
average number of peptide 1 per BSA was calculated by averaging the number of 
amino acids for each preparation with or without cysteine residue. Error bars 
represent 95 % confidence limit. 
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Fig. 8 (A) Amino acid analysis 
25 
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Fig. 8 (B) Average number of peptides per BSA 
30 
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Fig. 9. Reconstitution of nuclear membranes 
Nuclear membranes were reconstituted using Xenopus egg extracts and sperm 
DNA as described in the Appendix. D. Each pair of images consists of a 
fluorescent image of the DNA-binding dye, Hoechst 33258, on the left (Hoechst) 
and a phase contrast image on the right (Optical). 
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Fig. 10 Transport assay with FITC-labeled peptide 1, BSA and peptidel-
conjugated BSA 
To 20 J...Ll of reconstituted nuclei, 2 J...Ll of the following FITC labeled proteins were 
added. The assay mixture was incubated at the indicated temperatures and 
observed at the indicated times as shown below using different light filters; 
Sample Tern perature Final concentration 
J...Lg I J...Ll J...LM 
O.lx F-(BSA-Pepl) 0 °C 0.029 0.339 
lx F-BSA 0 °C 0.039 0.585 
lx F-peptide1 0 °C 0.024 17.5 
O.lx F-(BSA-Pep1) 25 °C 0.029 0.339 
lx F-BSA 25 oc 0.039 0.585 
1x F-peptidel 25 oc 0.024 17.5 
Fig. 10 A shows the results of the experiments with F-(BSA-peptide1) and Fig 10 
B shows the results of the experiments with F-BSA and F-peptidel. Each pair of 
images consists of a fluorescent image of the DNA-binding dye, Hoechst 33258, 
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Fig. 11 Accumulation of FITC-labeled oligonucleotides in reconstituted nuclei 
To 20 ~l of reconstituted nuclei, 2 ~l volumes of the following FITC labeled DNA 
were added and incubated at the indicated temperatures as shown below. In the 
experiments performed with 1x F-DNA, samples were observed at 0, 15, 30, and 
60 min after the FITC-labeled oligonucleotide additions (Fig. 11 A) . In the 
experiments performed with F-DNA diluted ten times (0.1x F-DNA), samples 
were observed at 0, 60 and 120 min after the FITC-labeled oligonucleotide 
addition using different filters under a fluorescence microscope (Fig. 11 B). 
Each pair of images consists of a fluorescent image of the DNA-binding dye, 
Hoechst 33258, on the left (Hoechst) and a fluorescent image of fluorescein on the 
right (Fluorescein). 
Sample Temperature Final concentration 
~g/~1 ~M 
1xF-DNA 0 °C 0.36 54.0 
1xF-DNA 25 oc 0.36 54.0 
0.1x F-DNA 0°C 0.036 5.4 














































































Fig. 12. Accumulation of TRITC-labeled oligonucleotides in the reconstituted 
nuclei 
To 20 !J.l of reconstituted nuclei, 2 !J.l volumes of the following TRITC 
(tetramethylrhodamine isothiocyanate)- labeled DNA were added at room 
temperature. Observations were made at the indicated times using different 
filters under a fluorescence microscope. Each pair of images consists of a 
fluorescent image of the DNA-binding dye, Hoechst 33258, on the left (Hoechst) 
and a fluorescent image of tetramethylrhodamine on the right (Rhodamine) . 
Sample Temperature Final concentration Observation 






































































Fig. 13. Simultaneous uptake of FITC labeled BSA-signal peptide conjugates 
and TRITC-labeled oligonucleotide 
The following combinations of protein and oligonucleotide were added to 
reconstituted nuclei at room temperature to the final concentrations as shown 
below. Each row of images consists of a fluorescent image of the DNA-binding 
dye, Hoechst 33258, on the left (Hoechst) and fluorescent images of fluorescein in 
the middle (Fluorescein) and that of tetramethylrhodamine on the right 
(Rhodamine). 
Sample Final concentration Observation 
!lgl!ll !lM 
O.lx F-(BSA-P1)/0.1x R-DNA 0.027/0.014 0.311/2.067 90,120 min. 
0.1x F-(BSA-P1) /- 0.027/- 0.311/- 90 min. 



























































































Fig. 14. Time-differential Dual label Experiment 
Reconstituted nuclei were incubated with fluorescein-labeled BSA-peptide 1 
conjugate (F-(B-P1), 0.339 J..LM) for 60 min in order to identify transport-
competent nuclei. At the end of incubation, the reconstituted nuclei were chilled 
on ice for 20 min to stop the transport process. After this, the medium containing 
the reconstituted nuclei was divided into two fractions. One was incubated on 
ice for 5 min and the other was incubated at room temperature for 5 min. At the 
end of this incubation, TRITC-labeled oligonucleotides (R-DNA, to a final 4.5 
J..LM) or TRITC-labeled BSA-peptide 1 conjugates (R-(B-P1), to a final 0.22 ~-tM) 
were added to each fraction and the fluorescence associated with the nuclei was 
observed at the indicated times using different filters under a fluorescence 
microscope . Each row of images consists of a fluorescent image of the DNA-
binding dye, Hoechst 33258, on the left (Hoechst) and fluorescent images of 




















































































































































































































Fig. 15. Effect of nuclear localization signal peptide 
on the nuclear acumulation of oligonucleotides 
The following FITC labeled samples were added to reconstituted nuclei to the 
following concentrations, incubated at room temperature, and observed under 












0 and 120 min. 















































































































Fig. 16. Nuclear localization activity of peptide 1 and FITC-labeled peptide 2 
To 20 IJ.l of reconstituted nuclei, 2 IJ.l volumes of the following FITC labeled 
proteins were added, incubated at room temperature, and observed under 
microscope at the indicated times. Each pair of images consists of a fluorescent 
image of the DNA-binding dye, Hoechst 33258, on the left (Hoechst) and a 













0, 60, and 160 min. 















































































































































































Appendix. A. Cell culture media 



























































D-Ca pantothenate 4.00 
Choline chloride 4.00 





Thiamine· HCl 4.00 
*1. Dulbecco, R., Freeman, G. (1959) Virology 8, 396. 
2. Smith, J.D., Freeman, G., Vogt, M and Dulbecco, R. 
(l960)Virology 12, 185. 
3. Tissue culture Standards Committee, In Vitro 6:2, 93 
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2. A recipe for folate-deficient DMEM 
1. Vitamin stock solution containing the following components at the 
indicated concentration is made in deionized water and 40 rnl is used for 
1 liter fdDMEM. Stock solution is kept at -20 °C. 
D-Ca patothenate 100.00 rng/L 
Choline chloride 100.00 rng/L 
i-Inositol 200.00 rng/L 
Nicotinamide 100.00 rng/L 
Pyridoxal·HCl 100.00 rng/L 
Riboflavin 10.00 rng/L 
Thiarnine·HCl 100.00 rng/L 
2. The following parts (Cat. No) from Gibco Lab. are mixed for 1 liter 
rnedi urn as follows; 
Earle's balanced salt solution (450-1100) 1.0 package/L 
Basal medium Eagle supplements 
(lOOx amino acid solution, 320-1051AG) 40.00 rnl/L 
1 M HEPES buffer solution (380-5630AG) 21.00 rnl/L 
100 rnM MEM sodium pyruvate solution 
(320-1360AG) 10.00 rnl/L 
200 rnM L-glutarnine solution 
(lOOx, 320-5030AG) 20.00 rnl/L 
3. The following stock solutions are made and the indicated volume is used 
for 1liter medium as follows; 
Cornponernt Stock solution Volurne/L 
Fe(N03)3.9H20 10.00 rng/rnl 10.00 111/L 
Glycine 10.00 rng/rnl 3.00 rnl/L 
L-Serine 10.00 rng/rnl 4.20 rnl/L 
4. 2.2 g NaHC03 is added to the mixture for 1liter medium. 
5. Fungi-Bact solution (penicillin G 10,000 units/rnl, streptomycin sulfate 
10,000 rng/rnl, fungizone 25 rng/rnl in normal saline, Irvine Scientific, 
Santa Ana, CA. Cat No. 9350) 10 rnl is used for 1 liter m edium. 
6. Deionized water is added to the mixture to a final vol urne of 900 rnl and 
pH is adjusted to 7.3 using 1 N NaOH solution. 
7. For ce ll culture m edium (fdDMEM, 5 % FCS), 50 rnl fetal calf serum 
(Hyclone Laboratories, Inc., Cat. No. A-1111-L, heat-inactivated at 65 oc 
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for 30 min.) is added to the above 900 ml solution and final volume is 
adjusted to lliter. For folate uptake assay medium (fdDMEM), fetal calf 
serum is not added and final volume is adjusted to lliter. 
8. Media are filtered using two CN 0.2 ~m Nalgene disposable filterwares 
(500 ml size) and kept at 4 °C. 
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Appendix. B. Procedures for radioiodination 
Radioiodination using Iodo-beads (Pierce Chemical Company, Cat. 28666)** 
1. 10 particles of Iodo-beads (Pierce Chemical Company, Cat. 28666) are 
washed in 50 mM Tris buffer (pH7.5) in a petridish and dried on 
Whatman #1 filter paper. 
2. 200 )11 of 50 mM Tris buffer (pH7.5) is added to 10 )ll(lmCi) Na125I 
(Amersham). 
3. 100 )11 diluted Na125I solution is added to each Eppendorf tubes 
containing 5 iodo-beads and left for 5 min. at room temperature. 
4. 100 )1150 mM Tris buffer (pH7.5) is added to 100 )ll diluted Na125I 
solution containing iodo-beads. 
5." To each tube containing iodo-beads, about 2 mg of protein in 50 mM Tris 
buffer (pH7.5) (protein oncentration = 10 mg/ml) is added and left for 1 
hour for iodination. 
6. Reacted protein solution is transferred to clean Eppendorf tubes by 
pippetting to stop reaction 
7. 125!-labeled protein is separated from unreacted 125I using gel-filtration 
chromatography. Sephadex G-25 (Sigma) column (1.5x35 em) is made 
and reaction mixture is loaded on the column and eluted using 50 mM 
Tris buffer (pH7.5). 
8. Eluted fractions are collected and 10 ).l.L aliquots from each fraction are 
analysed for radioactivity using a g-counter or a scintillation counter. 
9. Radioactive fractions containing iodinated protein are identified and 
protein concentrations are determined using an appropriate protein 
assay. Radioiodinated proteins are kept frozen at -20 °C. 
**Markwell, M.A. K. (1982) Anal. Biochem. 125,427-432 
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Appendix. C. Peterson's modified Lowry assay 
1. Stock solutions for Peterson's modified Lowry protein assay*** 
A: 20% Na2C03 solution (20 g Na2C03 in 100 ml water solution, filtered 
using CN 0.2 ~m N algene disposable filterware and kept at 4 °C.) 
B: 0.4% CuS04·5H20 (0.4 gin 100 ml water solution) 
C: 0.8% Na2 tartarate·2H20 (0.4 gin 100 ml water solution) 
D: 10% sodium dodecyl sulfate (lOOg in 1liter solution) 
E: 0.8NNaOH 
F: 0.4 N Folin-Ciocalteu's phenol reagent (diluted from 2 N stock 
solution, Sigma, Cat. F-9252) 
2. Procedures for protein determination 
1. Bovine serum albumin standard solutions and unknown protein 
samples (concentration range 0-250 ~g/ml) are prepared in 1 ml water 
in 13x100 ml test tubes in duplicate. 
2. The following 'assay solution' is made by mixing the stock solutions as 
follows and warmed to 37 octo prevent precipitation; 
1 volume of A 
0.5 volume of B 
0.5 volume of C 
2 volumes of D 
2 volumes of E 
2 volumes of water 
3. To 1 ml protein samples, 1 ml 'assay' solution is added and mixed 
thoroughly by vortexing. The mixture is incubated at room temperature 
for 15 minutes. 
4. To the mixture made in 3., 0.5 ml of 0.4 N Folin-Ciocalteu's phenol 
reagent is added and mixed thoroughly by vortexing. The reaction 
mixture is incubated at room temperature for 45 minutes. 
5. Absorbance is measured at 540, 660, or 750 nm using a UV-Visible 
spectrophotometer. 
6. Protein concentrations are calculated using BSA as standards. 
***Peterson, G. L. (1977) Analytical Biochemistry 83, 346-356 
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Appendix. D. Reconstitution of cellular nuclei using Xenopus egg extracts 
and sperm nuclei**** 















0.2 M 7.608 g EGTA (M.W. 380.4) in 
about 60 ml H20, titrated to pH 
8.0 with 10 N NaOH (or KOH). 
Water is added to a final 100 ml 
volume. 
10.0 mg/ml 5 mg each of the Chymostatin, 
Leupeptin, Pepstatin A (Sigma) 
are dissolved in 0.5 ml DMSO 
and kept at -20 °C. 
10.0 mg/ml 5.0 mg/ml cytochalasin B (from 






















L-Cysteine 4 g is dissolved in 200 
ml distilled water and 10 M 
N aOH is added to pH 7.8 at room 
temperature. It is important to 
prepare it just before use. It 
looses its dejellying activity in 
several hours by air oxidation 
Cycloheximide is prepared in 
distilled H20 and kept at -20 °C. 
preparation 
29.225 g 
4.0 ml 2.5 M KCl 
10.0 ml 0.5 M MgCl2 
10.0 mll.O M CaCh 
2.5 ml 0.2 M Na-EGTA, pH 8.0 
3.03 g 
Add distilled water to 400 ml volume to the above mixture and 
titrate with concentrated HCl to pH 7.8. Add distilled water to a 
final volume of 500 ml. Keep it at 4 °C. 
lx MMR buffer (500 ml per each experiment) 
component cone. preparation 
NaCl 100.00 mM 2.9225 g 
KCl 2.0 mM 0.4 ml 2.5 M KCl 
MgCl2 1.0 mM 1.0 ml 0.5 M MgCh 
CaCl2 2.0 mM 1.0 ml 1.0 M CaCh 
Na-EGTA 0.1 mM 0.25 ml 0.2 M Na-EGTA, pH 8.0 
Tris (base) 5.0 mM 0.303 g 
Add distilled water to 400 ml to the above mixture and titrate with 
concentrated HCl to pH 7.8. Add distilled water to a final volume 
of 500 ml. 
Alternatively lOx MMR is diluted to lx MMR. 
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HEPES (not salt) 100.0 mM 
Sucrose (342.3) 500.0 mM 
preparation 
74.6g 
1.0 ml 1.0 M CaCl2 
10.0 ml 0.5 M MgCl2 
23.8g 
171.15 g 
Add distilled water to a volume of 800 ml to the above mixture and 
titrate with 10 M KOH to pH 7.7. Add distilled water to a final 
volume of 1,000 ml. Keep it at 4 oc. 
lx XB (Extract buffer) (lliter) 
Add 100 ml lOx XB to 900 ml distilled water. Titrate with 10 M 
KOH to pH 7.7. 
lx XB' (lx XB supplemented with 5 mM K-EGTA and 1 mM MgCl2, 1 
liter) 
preparation 
100 ml lOx XB 
2.0 ml 0.5 M MgCl2 
25.0 ml 0.2 M K-EGTA, pH 8.0 
Add distilled water to 1liter and titrate with 10M KOH to pH 7.7. 
lx XB' +CLP+CB (XB' with protease inhibitors and cytochalasin B) 
preparation 
1.0 ml 1x XB' 
4.4 J.ll 10 mg/ml CLP in DMSO 
13.2 J.ll 10 mg/ml CB in DMSO 





0.2 M creatine phosphate (sigma, pH 7-8 when 
prepared) 
0.1 M ATP(Na2ATP, Boeringer Manheim, titrated to 
pH 7.0 with 10M KOH using pH paper (color pHast R 
indicator strips) 
K-EGTA, pH 7.7 
O.SMMgCl2 
distilled H20 
Hoechst dye mixture 
preparation 
2.0 ~1 10 mg/ml Hoechst 33258 (Sigma) in H20 
100 ~1 37 % formaldehyde 
1.0 ml buffer A/ sucrose (80.0 mM KCl, 5.0 mM K-EGTA, 
15.0 mM piperazine-N,N'-bis[2-ethanesulfonic acid], 
pH7.2, 15.0 mM NaCl, 7.0 mM MgCl2 and 200.00 mM 
sucrose) 
(2) Preparation of Xenopus sperm DNA 
1. Inject 0.1 ml of gonadotropin to a male frog. After incubate for an hour , 
take out the testis and put it in 50 ml 1x MMR supplemented with 0.25 
ml HCG (l,OOOunits/ml, Sigma). Incubate it overnight at 18 °C. 
2. Take off the blood vessels from the surface of the testis. 
3. Cut the testis into small pieces in 2 ml buffer A/ sucrose. 
4. Mush the pieces of testis in a small beaker. 
5. Put all the pieces into 4 Eppendorf tubes (1.5 ml). 
6. Spin the tubes for 30 seconds at setting 4 on the IEC clinical centrifuge. 
7. Trnsfer the supernatant into 4 Eppendorf tubes (1.5 ml). 
8. Spin the tubes for 1 min at setting 7 on the IEC clinical centrifuge. 
9. Remove the supernatant and wipe the wall of the tubes. 
10. Add 100 ~1 of lysolecitin solution (Sigma, 0.1 % in buffer A/sucrose) to 
each tube. Suspend the pellet by pipetting. 
11. Incubate the sperm in the above solution for 10 min at room temperature 
to lyse the sperm membranes. 
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12. Check the lysis of the membrane by staining the sperm DNA with 
Hoechst dye mixture (stained if lysed). 
13. Spin the sperm DNA at setting 5 for 10 seconds on the IEC clinical 
centrifuge. 
14. Add 0.3 ml of 3 % BSA in buffer A/ sucrose to each tube and mix 
thorough! y. 
15. Spin for 3 min at setting 5 on the IEC clinical centrifuge. 
16. Add 0.5 ml3 % BSA solution and resuspend the pellet. 
17. Spin for 3 min at setting 5 on the IEC clinical centrifuge. 
18. Add 0.5 ml3% BSA solution and resuspend the pellet. 
19. Spin for 3 min at setting 5 on the IEC clinical centrifuge. 
20. Resuspend the pellet in 0.3 ml of buffer A/ sucrose and count the 
number of sperms per j..ll. Dilute the sperm solution to a final 
concentration of 10s ea/j..ll. Aliquots are kept at -80 oc. 
(3) Frog priming and inducing ovulation 
1. Priming frogs; Frogs are maintained in charcoal filtered water. Prime 
the frogs by injecting 100 units of Pregnant Mare Serum Gonadotropin 
(PMSG, Calbiochem) on day 1. Frogs are kept at 18 °C in 5 liter water 
containing 25 g NaCl after priming. When handling frogs, wear plastic 
gloves which were washed inside and out with water to remove 
powder. 
2. Inducing ovulation; Prepare human chorionic gonadotropin solution 
(HCG, Sigma) by adding 10 ml distilled and sterilized water to 10, 000 
units of lyophilized HCG. Add 25 g NaCl to 5 liters of distilled water in 
which the frogs will lay eggs. Using 3 cc sterile syringe and 21Gl 
needle, take out HCG solution. Using 23Gl needle, inject 0.8 ml HCG 
solution per each primed frog into the dorsal lymph sac (under the skin 
of thigh) between day 3 and 14. Inject hormone at 4-8 PM to 2-3 frogs 
and the frogs will usually finish laying eggs before noon the next day. 
Put the frogs in the saline solution separately. 
(4) Preparation of cytostatic factor (CSF) arrested extracts 
1. Transfer the frog eggs from one frog to a 200 ml glass beaker. Wash the 
eggs with 100-200 mllx MMR at room temperature. 
2. Dejelly the eggs using freshly made 2 % cysteine, pH7.8 solution. First, 
add 100 ml cysteine solution to the eggs and gently swirl the eggs with a 
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glass pipette. Add second 100 ml cysteine solution and swirl gently 
until the gelly wrapping the eggs are dissolved and the eggs are packed 
on the bottom of the beaker. Decant the supernatant solution. 
3. Wash the eggs with about 100 ml 1xMMR twice at room temperature. 
Care must be taken not to break the eggs. Do not decant all the buffer 
since the surface tension could break the eggs. 
4. Wash the eggs 4 times with about 100 mllxXB' buffer (1xXB, 5 mM K-
EGTA, 1 mM MgCl2). 
5. Transfer the eggs (about 1 ml) to ultracentrifuge tubes (11x34 mm, 
7 /16x13/8 inch., Beckman) placed in a rack for 1.5 ml Eppendorf tubes. 
Use a glass pipette of which the sharp portion is broken and covered 
with a rubber bulb. Use the wide mouth of the pippette in order not to 
damage the eggs when trasfering the eggs to centrifuge tubes. 
6. Add 0.5 ml XB'+CLP+CB to each tube containing eggs. Cover the tube 
with a piece of parafilm and invert the tube a few times gently so that 
the buffer smears between the eggs. 
7. Pack the eggs on a clinical centrifuge (International Equipment ompany) 
as follows; Centrifuge the eggs for 15, 60 and 30 seconds at speed 
controls of 3, 5 and 7, respectively. Remove excess buffer. 
8. Crush the eggs by spinning the eggs at 12,000 rpm for 10 min at 16 oc 
on a TLS-55 swing bucket rotor in Beckman TL-100 ultracentrifuge. 
9. After centrifugation, the eggs are crushed into three fractions; from top 
to the bottom, yellow yolk, cytoplasmic fraction and membrane debris. 
Recover the cytoplasmic (middle) fraction with 21G1 needle and 3 cc 
syringe by puncturing the ultracentrifuge tube and transfer it to an 
Eppendorf tube placed on ice. 
10. Transfer the egg extracts to 0.5 ml long and skinny centrifuge tubes 
(Beckman) using a glass pipette and spin them for 2 min at 4 °C using a 
Beckman minifuge. 
11. After centrifugation, cut the skinny tube with a razor blade to remove 
the yolk on top of the extracts and transfer the extracts to pre-weighed 
Eppendorf centrifuge tube. Measure the weight of the extracts quickly 
and place the extracts on ice. The weight is used to calculate the 
approximate volume of the extracts. 
12. Add 1/19th volume of 20x Energy mix to the egg extracts on ice. 
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13. Add 1/lOOth volume of cycloheximide (10 mg/ml stock in H20) to the 
egg extracts on ice to stop the protein synthesis in the extracts. 
14. Add Xenopus sperm nuclei to a final concentration of 500 ea./Ill extract. 
15. Add 100 mM CaCb to a final concentration of 0.4 mM and mix well 
gently in order to activate the cycling of the extracts at room 
temperature. If the extracts are activated, nuclear membranes are 
formed around the sperm nuclei in 5-10 min, which can be visualized 
under a phase contrast microscope (Zeiss Axioplan microscope) at a 
400x magnification. 
16. After 10-20 minutes of activation, add 2 Ill of proteins or DNA with 
proper fluorescent labels to 20 Ill of the activated extracts at room 
temperature and incubate for appropriate periods. 
**** 
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